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Abstract. A series of 75 guanidine and 2-aminoimidazoline analogue molecules were 
assayed in vitro against Trypanosoma brucei rhodesiense STIB900 and Plasmodium 
falciparum K1. The dicationic diphenyl compounds exhibited the best activities with 
IC50 values against T. b. rhodesiense and P. falciparum in the nanomolar range. Five 
compounds (7b, 9a, 9b, 10b, and 14b) cured 100% of treated mice upon ip 
administration at 20mg/kg in the difficult to cure T. b. rhodesiense STIB900 mouse 
model. Overall, the compounds that bear the 2-aminoimidazoline cations benefit from 
better safety profiles than the guanidine counterparts. The observation of a correlation 
between DNA binding affinity at AT-sites and trypanocidal activity for three series of 
compounds supported the view of a mechanism of antitrypanosomal action due in part 
to the formation of a DNA complex. No correlation between antiplasmodial activity and 
in vitro inhibition of ferriprotoporphyrin IX biomineralisation was observed, suggesting 
that additional mechanism of action (MOA) is likely to be involved.  
 
Key words: chemotherapy; plasmodium; trypanosome; guanidine; imidazoline; 
malaria; sleeping sickness; DNA minor groove binding; hemozoin.  
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Introduction 
Infectious diseases caused by protozoan parasites are responsible for great morbidity 
and mortality mainly in the least developed countries. Despite the lack of significant 
research investment on tropical diseases, rich countries recently started to pay attention 
to malaria because this disease also represents a potential threat for the developed 
world. Another tropical disease, human African trypanosomiasis (HAT or sleeping 
sickness) is only present in sub-Saharan Africa and affects between 50.000 and 70.000 
people.
1
 HAT belongs to the most neglected diseases as defined by a World Health 
Organization/Industry working group.
2
  
Drugs available for HAT are obsolete and present unacceptable adverse effects, as 
well as increasing treatment failures due to emergence of drug resistance or other 
reasons.
3–5
 On the other hand, the chemotherapy of malaria is principally impaired by 
the appearance of drug resistant strains of Plasmodium spp.. Hence, chloroquine which 
was the most common antimalarial drug for decades is now practically ineffective and 
emergence of resistance to other drugs such as mefloquine, halofantrine or artemisinin 
is beginning to appear.
6
 For those reasons, WHO now recommends the use of 
antimalarial drug combinations (e.g., artesunate/mefloquine, artesunate/amodiaquine) in 
order to delay the development of resistant strains.
5
 Thus, the discovery of new safe and 
efficient antiprotozoal agents to treat HAT and malaria is a priority in international 
health.  
Recent findings by our group have shown that bisguanidine and especially bis(2-
aminoimidazoline)diphenyl compounds displayed potent antitrypanosomal activity in 
vitro and vivo against T. b. rhodesiense, the causative agent of acute HAT.
7, 8
 These 
studies revealed that compounds bearing 2-aminoimidazoline cations (scaffold A, Chart 
1) had higher selectivity for the parasite and similar activities with respect to their 
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guanidine counterparts. In addition, a correlation between antitrypanosomal activity and 
DNA binding affinity was observed, suggesting a possible mechanism of action for 
these compounds.
7
 Finally, we showed that this class of compounds (i.e., 1a and 1b) 
entered into trypanosomes via different transporters in addition to P2, indicating that 
parasites that have lost the P2 transporter in selection of resistance to other drugs will 
not show cross-resistance to this class of compounds. Encouraged by these promising 
results, another series of 16 dicationic analogues (3–4, 7–11, 13b and 14, Table 1) was 
evaluated against T. b. rhodesiense and their DNA binding affinity at AT-rich sites was 
estimated by ∆Tm measurements with a nonalternating AT sequence DNA polymer.9  
Others have described excellent antiplasmodial activity of related aromatic dicationic 
structures such as pentamidine or DB75.
10–13
 For example, DB289, the neutral prodrug 
of DB75, has been used to treat uncomplicated P. vivax and P. falciparum malaria.
14
 
Stead et al. demonstrated that uptake of pentamidine into infected erythrocytes proceeds 
via a route similar to the new permeability pathway (NPP). In addition, it has been 
proposed that these diamidines share a common MOA with chloroquine by binding to 
ferriprotoporphyrin IX and inhibiting the formation of hemozoin.
15
 These findings 
prompted us to test the antiplasmodial potential of our dicationic diphenyl compounds 
(Chart 1, scaffold A).
9
 The capacity of the compounds to inhibit the formation of 
hemozoin as possible mechanism of antiplasmodial activity was also evaluated in vitro 
with the ferriprotoporphyrin IX binding inhibition test (FBIT).
16
 
Moreover, in order to extend our understanding of the SAR of this class of 
antiprotozoal agents two new series of cationic analogues, namely 2-
aminoimidazolinium compounds and their guanidinium counterparts (Chart 1: scaffolds 
B and C) were selected for in vitro screening on T. b. rhodesiense and P. falciparum. As 
can be shown in Chart 1, the three analogous series are strictly structurally related one 
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to each other: scaffold A represent the “full” dicationic diphenyl model compound. 
Scaffold B is analogous to A but devoid of one cationic group whereas scaffold C has 
“lost” one cationic moiety and one phenyl ring. With these series in hand, we intend to 
demonstrate the significance of each part of the molecule for the overall activity of the 
dicationic diphenyl compounds and gain insight into the SAR of this series of 
antiprotozoal compounds. 
Finally, to check whether the activity was maintained in vivo, the most active and 
selective compounds in vitro were assayed in an acute HAT mouse model (T. b. 
rhodesiense STIB900) or rodent malaria model (P. berghei GFP ANKA). Several lead 
compounds with excellent in vivo activity emerged from this screening. 
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Chart 1. General structures of the compounds studied highlighting the skeleton 
common to the different scaffolds. 
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Results 
Chemistry 
Many of the compounds presented here were previously synthesised by us for other 
purposes. The synthesis of 1a–e, 2a–c, 5a–f, 6a–e and 12a–b was described earlier.
8, 17
 
The synthesis of compounds 3a–b, 4a–b, 15a–b, 17a–b, 18b, 24–26a–b, 29a–b, 31a–b, 
33–35a–b and their Boc-protected precursors was described in a recent paper of F. 
Rodriguez et al.
18
 The synthesis of 10a–b, 13b, 14a–b, 16a–b, 27a–b, 28a, 32a–b, 
36a–b, 37b and their Boc-protected precurors will be reported elsewhere.
19 The 
synthesis of 7a–b, 8a, 9a–b, 11a–b, 19–23a–b and 30a–b is described in Schemes 1 
and 2. Amongst these derivatives, 7a, 11a–b, 19a–b, 20a–b, 21a–b, 22b, and 23b (in 
addition to all the Boc-protected precursors) are new, whereas 7b,
20
 8a,
21
 9a,
22
 9b,
23
 
22a
24, 25
 and 23a
22
 have been previously described in the literature using different 
synthetic strategies. Briefly, our synthetic approach to introduce the guanidine and 2-
aminoimidazoline groups relied on the reaction between primary amines or diamines 
and N,N’-bis(tert-butoxycarbonyl)thiourea/HgCl2/Et3N
26
 or N,N’-bis(tert-
butoxycarbonyl)imidazoline-2-thione/HgCl2/Et3N,
17
 affording the Boc-protected 
guanidines (7d, 9d, 11d, 19d, 20d, 22d, 23d and 30d) and 2-aminoimidazolines (7e, 9e, 
11e, 19e, 20e, 22e, 23e, and 30e),  respectively. Removal of the Boc protecting groups 
with TFA followed by anion exchange chromatography afforded the hydrochloride salts 
of the compounds 7a–b, 8a, 9a–b, 11a–b, 19a–b, 22a–b, 23a–b, and 30a–b. 
Compounds 20a, 20b, 21a and 21b were studied as their trifluoroacetate salts (Scheme 
1). In the case of the thiourea derivatives 8d, 21d and 21e, an alternative strategy was 
employed to avoid the competitive reaction occurring between the thiourea linker of the 
starting material (i.e., 8 and 21) and the thiourea guanidine precursors for the HgCl2 
catalyst (Scheme 1). Hence, 8d was obtained by condensation of the monomer 8
18
 in an 
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excess of carbon disulfide.  Alternatively, the reaction of 8 with one equivalent of 
phenylisothiocyanate in CH2Cl2 afforded the guanidine derivative 21d (68%). 
Compounds 20d and 23d could also be synthesized in a similar way by reaction of 8 
with phenyl isocyanate or  benzoyl chloride, respectively. A similar approach was used 
for the synthesis of the 2-aminoimidazoline analogue 21e starting from 8b. Thus, 1,4-
phenylenediamine was reacted with one equivalent of N,N’-bis(tert-
butoxycarbonyl)imidazoline-2-thione/HgCl2/Et3N,
17
 to afford the monomer 8b. The 
crude product 8b was reacted without further purification with 1 equiv. of 
phenylisothiocyanate, yielding 21e after chromatography on neutral alumina (22% for 
two steps). Four of the starting material amines (7,
27
 11,
28, 29
 20 and 22) were obtained 
in a straightforward manner as depicted in Scheme 2. 
 
Biological results 
In Vitro Activity. Structure–Activity Relationships. 
The results of the in vitro antitrypanosomal and antiplasmodial activity are presented 
in Tables 1, 2 and 3. In order to gain insights into the mechanism of antiplasmodial and 
antitrypanosomal activity, the most active compounds (i.e., diphenyldicationic 
derivatives, scaffold A) were also tested as inhibitors of β-hematin formation16 and as 
DNA minor groove binders.
30
   
Antitrypanosomal activity. In general, the presence of two cations (scaffold A) was 
essential to get nanomolar anti-T. brucei activity. Accordingly, compounds with only 
one cation and no phenyl ring in para position (scaffold C) showed micromolar range 
IC50. The 1-(2,3-dihydro-1H-inden-5-yl)guanidine derivative 32a (IC50 = 0.99 and 0.95 
µM against T. b. rhodesiense and P. falciparum, respectively) was the most active 
molecule of this series. On the contrary, the scaffold A compounds displayed nanomolar 
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activities with the exception of the compounds with an electron-attracting group such as 
SO2 (6a, 6b and 6e) or CO (5b) linking both phenyl rings. Removal of one cationic 
moiety (scaffold B) or one phenyl-cationic moiety (scaffold C) led to a great loss of 
activity (e.g., compare 1a/15a/24a, 2a/16a/27a, 2b/16b/27b). Interestingly, the decrease 
in activity observed in homologous series with the removal of one cationic moiety (i.e., 
scaffold A → B) was less pronounced for the bis(2-aminoimidazolinium) vs 
bisguanidinium compounds [e.g., compare 1a/15a (×218) vs 1b/15b (×17), 2a/16a 
(×98) vs 2b/16b (×5.5), 3a/17a (×96) vs 3b/17b (×10)]. Another remarkable effect of 
the 2-aminoimidazolinium cation was the higher selectivity for the parasite observed in 
all the cases as compared with the guanidinium analogues [e.g., 3a (SI = 8) vs 3b (SI = 
88), 9a (SI = 319) vs 9b (SI = 7731), 14a (SI = 15) vs 14b (SI = 624)]. This observation 
was also true for the antiplasmodial activity of the dicationic compounds.  
Regarding the bridge linking both phenyl rings, the same range of activity (IC50 in the 
low micromolar range) was observed for electron donating groups: NH (1) ~ CH2CH2 
(10) >> piperidine (11) ~ piperazine (12). Isosteric replacement of the CH2 (2) by a 
sulfur (3) or oxygen atom (4) hardly changed the activity. The best activity was 
observed with an amide (9a, 9b) or ethane bridge (10a, 10b). Fused ring dicationic 
compounds 13 (fluorene) and 14 (dihydroanthracene) also gave excellent 
antitrypanosomal activity. The bis(2-aminoimidazoline)fluorene derivative 13b was the 
best anti-T. brucei agent in vitro (IC50 = 4.9 nM, SI = 17000). This outstanding value is 
to be compared with the guanidine analogue 13a (IC50 = 24 nM, SI = 196) previously 
described by Boykin and co-workers.
13
 Hence, replacement of the guanidine cations by 
2-aminoimidazoline ones led to a 5-fold increase in activity and 86-fold increase in 
selectivity for this scaffold.  
 9 
Dicationic guanidine compounds (scaffold A) with NH, CH2, O, S, CO or SO2 bridge 
linking both phenyl rings were 2- to 10-fold more potent than their 2-aminoimidazoline 
counterparts (compare 1a/1b, 2a/2b, 3a/3b, 4a/4b, 5a/5b and 6a/6b). The opposite 
effect was observed for monocationic compounds (scaffold B). However, no significant 
difference in antitrypanosomal activities was observed between the bisguanidine and 
bis(2-aminoimidazoline) counterparts for the compounds with the urea (7a, 7b), amide 
(9a, 9b) or ethane bridge (10a, 10b).   
 
Antiplasmodial activity. In most cases, the best activities for scaffolds A, B and C 
were observed for compounds bearing the 2-aminoimidazolinium cations except for the 
fluorene analogue 13b (IC50 = 11.5 nM), the activity of which was 5-fold lower than 
that reported by Boykin and co-workers for the guanidine counterpart 13a (2.3 nM).
13
 
Among twenty dicationic compounds, which displayed IC50 values < 50 nM, 
diphenylamine derivative 1b is the best antiplasmodial agent of the series (IC50 = 8.8 
nM, SI = 24000). Most of the dicationic compounds displayed excellent antimalarial 
activities regardless of the linker X. However, compounds with an electron withdrawing 
linker [SO2 (6), CO (5), NHCSNH (8)], exhibited somewhat lower activity. The 
remarkable in vitro antiplasmodial activities of the piperazine derivatives 12a and 12b 
(IC50 = 15.2 and 12.3 nM, respectively) were comparable to that of their diamidine 
homologue reported by Mayence et al. (IC50 = 4 nM).
10
 As observed for the 
antitrypanosomal activity, the removal of one cationic moiety from scaffold A 
compounds produced a dramatic loss of activity [Tables 1 and 2: compare 1b/15b 
(×62), 2b/16b (×108), 3a/17a (×171), 3b/17b (×150), 4b/18b (×48), 5b/19b (×40), 
7a/20a (×42), 7b/20b (×121), 8a/21a (×14), 9a/22a (×241), 9b/22b (>535)].  
 10 
The nanomolar activity observed for the uncharged Boc-substituted guanidine (1d) 
and imidazoline (1e, 6e) derivatives is worth noting. Interestingly, the bis(n-
pentylphosphonium) dicationic analogue 5f (IC50 = 53 nM, SI = 222) produced a 2-fold 
increase in activity together with a loss of selectivity with respect to its imidazoline 
counterpart 5b (IC50 = 129 nM, SI > 1658). Altogether, the data seems to indicate that 
lipophilic groups, either cationic (phosphonium derivative 5f) or uncharged (Boc-
protected compounds 1d and 1e), are allowed for good in vitro antiplasmodial activity 
of this class of symmetric diphenyl compounds. 
 
In Vivo Activity (Tables 4 and 5) 
The compounds displaying the best in vitro antitrypanosomal activities and selectivity 
were administered intraperitoneally to mice infected with T. b. rhodesiense STIB900. 
Five compounds (7b, 9a, 9b, 10b and 14b) cured all mice at 20 mg/kg whereas 11b 
only cured 2/4 mice at this dose (Table 4). This data was somehow surprising because 
the in vitro activity and selectivity of 11b and the other compounds tested were similar. 
Another interesting finding was the enhanced antitrypanosomal activity and reduced 
toxicity of the piperidine compound 11b compared to the piperazine molecule 12a (i.e., 
12a was  toxic at 20 mg/kg in this model
7
). Apparently, the presence of tertiary amino 
groups in 12a and 11b is not favourable for good in vivo activity which may possibly 
relate to unfavourable pharmacokinetic properties of the compounds. 
Hence, the in vivo activity of the new compounds in the difficult to cure STIB900 
mouse model was comparable to that of the lead compound 1b reported earlier.
7
 
Additional experiments to determine the minimum curative dose, oral bioavailability 
and potential activity in the chronic CNS mouse model of sleeping sickness are 
ongoing.  
 11 
In addition, ten compounds were tested in the P. berghei mouse model to check 
whether the excellent in vitro antiplasmodial activity of the dicationic compounds was 
retained in vivo. Four compounds (1b, 3b, 4b and 12a) reduced significantly the 
parasitaemia upon ip treatment at 20–50 mg/kg but none of them was curative (Table 5). 
However, the bis(2-aminoimidazoline) derivative 4b reduced parasitaemia drastically 
(97.5%) at 50 mg/kg and was able to increase mice survival almost 2-fold compared to 
control animals. This activity compared favourably with that of the control drug 
chloroquine at 5mg/kg. Besides, the ip administration of 3b (30 mg/kg) produced an 
activity of 44.1% similar to its diamidine counterpart administered subcutaneously at 40 
mg/kg.
31
 Altogether, the data confirm the antimalarial potential of the diphenyl amine, 
diphenylether and diphenyl sulfide scaffolds.  
The rest of the compounds were either toxic at the tested dose of 50 mg/kg (7a, 10a, 
11a and 14a) or inactive (12b). Taken together, the in vivo results suggest that, in this 
series, guanidine derivatives are more toxic than their cyclic congeners in agreement 
with the higher SI observed in vitro for the 2-aminoimidazoline analogues.  
 
Insights into the mechanism of action. 
(1) DNA binding affinity. Many aromatic diamidines and diguanidines are strong 
DNA minor groove binders.
11, 32, 33
 Some evidence suggests that this interaction is 
responsible to some extent for the antiprotozoal activity frequently displayed by this 
class of compounds. We previously reported the existence of a correlation between 
DNA binding affinity to AT-rich sites and in vitro antitrypanosomal activity of some of 
the dicationic compounds presented here (1a, 1c, 2a, 2c, 5f and 1b, 2b, 5a, 12a, 12b).
7
 
In order to extend our knowledge of the structural requirements responsible for high-
quality DNA minor groove binding, and possibly good antiprotozoal activity, the 
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thermal melting curves (∆Tm) of the new set of compounds (3a–b, 4a–b, 7–11a-b, 13b 
and 14a–b) were determined using a nonalternating AT sequence DNA polymer. We 
used the same experimental conditions (i.e., low salt buffer) as reported before,
7
 thus 
allowing the comparison of the ∆Tm values of the entire series. The results of DNA 
binding of the previous set of compounds (1, 2, 5 and 12) and the new series (3, 4, 7–11, 
13, 14) are presented in Table 6. Overall, strong DNA binding was observed for this 
new series of dicationic compounds with ∆Tm values ranging from 20.1 to 47.1 ºC. The 
2-aminoimidazoline derivatives consistently displayed higher ∆Tm values (2 to 7 ºC) 
than the guanidine counterparts indicating that the ethylene bridge of the 2-
aminoimidazoline group confers some special features, possibly extra hydrophobic 
contacts with the walls of the groove that contribute positively to the binding of these 
compounds.
34
 Curiously, the opposite effect is usually observed when comparing series 
of dicationic benzamidines and their imidazolines analogues, the amidine group 
conferring habitually better minor groove binders than the imidazoline counterparts.
35–38
  
Most interesting was the correlation observed between in vitro antiprotozoal activity 
and DNA binding affinity for the set of 2-aminoimidazoline compounds. Hence, 
plotting ∆Tm versus IC50 against trypanosomes revealed the two to be correlated as 
shown in Figure 1a. In addition, a clear trend showing an increase in activity with an 
increase in ∆Tm was observed for the guanidine set of compounds (Figure 1b). The most 
exciting finding from this DNA binding affinity study was observed with the 2-
aminoimidazoline set of compounds, the SI of which correlated in a fairly good manner 
with the Tm increase (Figure 2). On the contrary, no correlation was observed for the 
guanidine set of analogues.  
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(2) Inhibition of β-hematin formation. Earlier studies have shown that several 
diphenyldiamidine compounds displaying antiplasmodial activity bind effectively to 
FPIX in vitro inhibiting the crystallization of toxic FPIX into non-toxic hemozoin. The 
result of this interaction would be responsible for the antimalarial activity of that class 
of compounds.
10, 15
 We decided to test whether our bisguanidine and bis(2-
aminoimidazoline) derivatives might work in the same way to evaluate this hypothesis. 
A simple in vitro assay,
16
 the detection by optical density measurement of solubilised β-
haematin remaining after contact with drugs, was used to assess the capacity of our 
compounds to inhibit hemozoin biomineralisation (Table 7). Some of the compounds  
inhibited hemozoin formation at micromolar concentrations comparable to that of 
quinine (IC50 = 324 µM)16 though higher than chloroquine (IC50 = 17.9 µM). However, 
no correlation between in vitro antiplasmodial activity and hemozoin inhibition was 
observed.  
 
Discussion 
Encouraged by the excellent in vitro and in vivo trypanocidal activity of a series of 
dicationic diphenyl compounds previously discovered by our group,
7
 we report a 
continued investigation of 2-aminoimidazoline and guanidine analogues as potential 
antiplasmodial and antitrypanosomal agents.  In vitro and in vivo data from three new 
series of derivatives revealed some important trends for the SAR of these compounds. 
In all the cases, the diphenyl dicationic compounds (scaffold A) were the most active 
antitrypanosomal and antiplasmodial compounds with IC50 values in the nanomolar 
range. These compounds were more efficient than their monocationic analogues which 
showed IC50 in the micromolar range (scaffold B) highlighting once more that the 
presence of two cationic groups is essential for consistent activity in this series. The 
 14 
same trend was reported earlier with amidine containing diphenyl ureas active against 
P. falciparum,
39
 guanidine diphenyl derivatives active against T. equiperdum,
21, 40
 or 
furamidine analogues.
33, 41
 In addition, some basic SAR emerged relating to the best 
linker between both phenyl rings (i.e., NH, NHCO and CH2CH2) and the best cation 
(i.e., 2-aminoimidazoline) to get selective compounds with good in vivo 
antitrypanosomal activity (Figure 3). Fused ring dicationic compounds (13 and 14) also 
exhibited excellent activity in agreement with the results reported earlier by Arafa et 
al.
13
 Interestingly, with regards to the linker between the two phenyl rings, our results 
agree to some extent with the findings of Turner
27
 for a series of bis[1,6-dihydro-6,6-
dimethyl-1,3,5-triazine-2,4-diamines]. Thus it appears that the 1,2-diphenylethane and 
fluorene moieties should be considered as good scaffolds for the design of symmetric 
dicationic antitrypanosomal drugs regardless of the cationic moiety present in the 
molecule.  
We do not have a clear explanation concerning the extra selectivity and lower in vivo 
toxicity observed in all the cases with the 2-aminoimidazoline cations in comparison 
with the guanidine one. One may speculate whether the higher lipophilicity and/or a 
reduced H-bond donating capacity play a role in the reduced toxicity of the imidazoline 
derivatives. On the other hand, the observation that the 2-aminoimidazoline derivatives 
consistently displayed higher DNA binding affinity than the guanidine counterparts and 
the correlation observed between selectivity and Tm increase for this series suggest that 
the formation of a DNA complex may be an important issue to explain the MOA and 
selectivity profile of these dicationic derivatives. This new and quite exciting 
observation indicates that more investigations on 2-aminoimidazolines as DNA minor 
groove binders and antiprotozoal agents are warranted.   
 15 
Of note was the excellent in vitro antiplasmodial activity of the urea dicationic 
derivatives 7a and 7b (IC50 = 96 and 28 nM, respectively). Similar activities had been 
reported for amidine-containing diphenyl ureas.
39
 Interestingly, Jiang and co-workers 
have also reported micromolar in vitro anti–P. falciparum activity of a monocationic 
diphenyl urea compound. That compound, WR268961, the structure of which is related 
to 20 (i.e., scaffold B), was an inhibitor of the recombinant P. falciparum aspartic 
protease plasmepsin II.
42
 This is relevant because plasmepsins are validated targets for 
antimalarial therapy
43–45
 and the activity of 7, 20 and 21 might be related to plasmepsin 
inhibition, even though this would need experimental confirmation.  
Another exciting finding was the nanomolar activity exhibited by the Boc-protected 
compounds (1d, 1e, and 6e) against P. falciparum K1. The fair FPIX biomineralisation 
inhibition displayed by 1e in the FBIT assay (IC50 = 170.7 µM) suggests that this 
compound could interfere in the heme detoxification process of the parasite. However, 
since these highly lipophilic precursors are uncharged molecules one might expect their 
pharmacodynamics to be different from the dicationic derivatives. 
Despite the lack of correlation between FPIX biomineralisation inhibition and in vitro 
activity against P. falciparum, the binding to FPIX might be responsible to some extent 
for the observed antiplasmodial activity and/or for the accumulation of the compounds 
into the parasites as shown previously for some diamidine drugs.
15
 However, care 
should be taken in the interpretation of these results as we have no evidence at this time 
that these inhibitors are able to reach the food vacuole of the parasite to target the heme 
detoxification pathway. Indeed,  additional MOA is likely to be involved since our 
dicationic compounds were less potent FPIX inhibitors than CQ whereas they showed 
nanomolar range activity about one order of magnitude superior to CQ against the P. 
falciparum CQ-resistant strain K1. 
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The diphenyl dicationic compounds retained only moderate activity in the P. berghei 
murine model, in contrast to CQ, which may possibly indicate unfavourable 
pharmacokinetic properties or a different MOA. On the other hand, the modest in vivo 
activity observed after ip administration in the P. berghei model does not necessarily 
mean that these diphenyl diguanidine compounds are poor antimalarials. In fact, some 
recent evidence suggests that the P. berghei mouse model might not be optimal to 
predict the activity of aromatic diamidines against human malaria.
11
 For instance, 
DB289 which showed only modest activity in the P. berghei mouse model has shown 
remarkable activity in a human trial against P. falciparum.
14
 For that reason, we believe 
that these families of compounds deserve more thorough investigations of their in vivo 
antimalarial action. 
 
Conclusion 
In order to extend our understanding of the SAR of the bis(2-aminoimidazoline) lead 
compounds reported earlier,
7, 8
  we have screened a new series of symmetric dicationic 
guanidine and 2-aminoimidazoline aromatic analogues against T. b. rhodesiense and P. 
falciparum. We have shown that, in this series, the 2-aminoimidazoline derivatives were 
safer (higher SI) and more potent in vivo against T. b. rhodesiense than their guanidine 
counterparts. Moreover, a correlation between DNA binding affinity and selectivity 
towards the parasite was observed indicating that high affinity binding to the minor 
groove of DNA may be part of their mechanism of antitrypanosomal action. This view
7
 
was also supported by the observation of a correlation between DNA binding affinity 
and trypanocidal activity of two series of compounds.  
Five new dicationic lead compounds (7b, 9a, 9b, 10b and 14b), upon ip 
administration of 20 (mg/kg)/day, cured 100% of treated mice in the T. b. rhodesiense 
 17 
STIB900 model. On the contrary, despite their excellent in vitro antiplasmodial activity 
and capacity in reducing the parasitaemia of mice infected with P. berghei, the 
dicationic compounds 1b, 2b, 3b, 4b, and 12a did not cure the animals in this model. 
However, the P. berghei mouse model may not be the best predictive model for this 
kind of dicationic compounds as we have pointed out before.  
In this study we also described the excellent in vitro antiplasmodial activity of non 
cationic Boc-protected guanidines and imidazolines as well as phosphonium 
derivatives, the in vivo antimalarial efficacy of which is currently being evaluated. 
Hence, more thorough investigation on the antiplasmodial activity of this class of 
compounds is warranted.     
In the light of these promising results, we believe that bis(2-aminoimidazoline) 
derivatives deserve more investigation as antiprotozoal agents and DNA minor groove 
binders. The synthesis and study of new derivatives and prodrugs of our lead 
compounds is ongoing and will be reported in due course. 
 
Experimental section 
Chemistry. All the commercial chemicals were obtained from Sigma–Aldrich, Fluka or 
Lancaster and were used without further purification. Deuterated solvents for NMR use 
were purchased from Apollo. Dry solvents were prepared using standard procedures, 
according to Vogel,
46
 with distillation prior to use. Chromatographic columns were run 
using Silica gel 60 (230–400 mesh ASTM) or Aluminium Oxide (activated, Neutral 
Brockman I STD grade 150 mesh). Solvents for synthesis purposes were used at GPR 
grade. Analytical TLC was performed using Merck Kieselgel 60 F254 silica gel plates or 
Polygram Alox N/UV254 aluminium oxide plates. Visualisation was by UV light (254 
nm). NMR spectra were recorded in a Bruker DPX–400 Avance spectrometer, operating 
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at 400.13 MHz and 600.1 MHz for 
1
H NMR and 100.6 MHz and 150.9 MHz for 
13
C 
NMR. Shifts are referenced to the internal solvent signals. NMR data were processed 
using Bruker Win–NMR 5.0 software. Electrospray mass spectra were recorded on a 
Mass Lynx NT V 3.4 on a Waters 600 controller connected to a 996 photodiode array 
detector with methanol, water or ethanol as carrier solvents. Melting points were 
determined using an Electrothermal IA9000 digital melting point apparatus and are 
uncorrected. Infrared spectra were recorded on a Mattson Genesis II FTIR spectrometer 
equipped with a Gateway 2000 4DX2–66 workstation and on a Perkin Elmer Spectrum 
One FT–IR Spectrometer equipped with Universal ATR sampling accessory. Sample 
analysis was carried out in nujol using NaCl plates. Elemental analysis was carried out 
at the Microanalysis Laboratory, School of Chemistry and Chemical Biology, 
University College Dublin. Analytical results were within ±0.4% of the theoretical 
(calcd) values except otherwise noted. 
1) Synthesis of the starting material amines. 
1,3-Bis(4-aminophenyl)urea (7).
27
 A suspension of 5 g (16.5 mmol) of 1,3-bis(4-
nitrophenyl)urea in methanol in the presence of 5% Pd–C (480 mg) was hydrogenated 
at atmospheric pressure and room temperature for 22 h. Afterwards, the catalyst was 
filtered through a pad of celite. The filter cake was rinsed with MeOH:DMF (1:1) and 
the solvent removed in vacuo to afford 3.9 g (97%) of 1,3-bis(4-aminophenyl)urea 7 as 
a white solid; 
1
H NMR (DMSO–d6): δ 4.73 (broad s, 4H, NH2), 6.51 (d, 4H, J = 8.0 Hz, 
Ar), 7.07 (d, 4H, J = 8.0 Hz, Ar), 8.08 (broad s, 2H, NH); 
13
C NMR (DMSO–d6): δ 
115.6, 121.8, 130.6, 145.0 (Ar), 154.8 (CO). 
1,4-Bis(4-nitrophenyl)piperidine (11f). A solution of 2.5 g (12.1 mmol) of 4-(4-
nitrophenyl)piperidine
28, 29
 and 1.712 g (12.1 mmol) of 1-fluoro-4-nitrobenzene in DMF 
(8 mL) was heated at 100 °C for 72 h. Afterwards, the solvent was removed in vacuo 
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and the residue obtained was recrystallised from CH3CN to yield 2.95 g (74%) of 1,4-
bis(4-nitrophenyl)piperidine 11f as a yellowish solid; mp 170–172 °C; MS (ESI
+
) m/z 
350.1105 [M+Na]
+
; IR (nujol) ν 1597, 1516 (NO2) cm
-1
; 
1
H NMR (DMSO–d6): δ 1.62–
1.80 (m, 2H, H3Pip.), 1.83–1.97 (m, 2H, H3Pip.), 2.99–3.19 (m, 3H, H2ePip + H4Pip.), 
4.16–4.31 (m, 2H, H2aPip.), 7.08 (d, 2H, J = 8.8 Hz, Ar), 7.56 (d, 2H, J = 7.8 Hz, Ar), 
8.06 (d, 2H, J = 8.8 Hz, Ar), 8.17 (d, 2H, J = 7.8 Hz, Ar); 
13
C NMR (DMSO–d6): δ 33.0 
(C3Pip), 42.7 (C4Pip.), 48.4 (C2Pip.), 113.9, 124.9, 127.2, 129.5, 137.6, 147.3, 154.8, 
155.7 (Ar). 
 
1,4-Bis(4-aminophenyl)piperidine (11). A suspension of 1.5 g (4.6 mmol) of 1,4-
bis(4-nitrophenyl)piperidine 11f in methanol in the presence of 5% Pd–C (185 mg) was 
hydrogenated at 3 bar and room temperature for 22 h. Afterwards, the catalyst was 
filtered off and the solvent removed in vacuo to afford 1.198 g (98%) of 11 as a navy 
blue solid; mp 156–158 °C; MS (ESI
+
) m/z 268.1802 [M+H]
+
; IR (nujol) ν 3365, 3297, 
3201 (NH2) cm
-1
; 
1
H NMR (DMSO–d6): δ 1.63–1.80 (m, 4H, H3Pip.), 2.32–2.43 (m, 
1H, H4Pip.), 2.53–2.61 (m, 2H, H2ePip.), 3.38–3.49 (m, 2H, H2aPip.), 4.58 (broad s, 2H, 
NH2), 4.85 (broad s, 2H, NH2), 6.46–6.54 (m, 4H, Ar), 6.73 (d, 2H, J = 8.8 Hz, Ar), 
6.92 (d, 2H, J = 8.3 Hz, Ar); 
13
C NMR (DMSO–d6): δ 35.1 (C3Pip.), 42.1 (C4Pip.), 53.3 
(C2Pip.), 115.4, 116.2, 120.0, 128.4, 134.9, 143.4, 144.5, 148.0 (Ar). 
 
1-(4-aminophenyl)-3-phenylurea (20). 1.10 mL (10.0 mmol) of phenyl isocyanate 
was added under an inert atmosphere and at 0 °C over a solution of 1.082 g (10.0 mmol) 
of 1,4-phenylenediamine in dry CH2Cl2 (10 mL). The mixture was allowed to reach 
room temperature and was stirred for 10 minutes. The white solid precipitated was 
filtered and washed with cold CH2Cl2 to afford 2.15 g (95%) of the pure 1-(4-
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aminophenyl)-3-phenylurea; mp decomposes over 212 °C (Lit.
47
: 260 ºC); IR (nujol) ν 
3353, 3292, 3181 (NH, NH2), 1622 (CO; Lit.
48
: 1630) cm
-1
; 
1
H NMR (DMSO–d6): δ 
4.80 (broad s, 2H, NH2), 6.56 (d, 2H, J = 8.5 Hz, Ar), 6.88–6.99 (m, 1H, Ar), 7.12 (d, 
2H, J = 8.5 Hz, Ar), 7.21–7.30 (m, 2H, Ar), 7.46 (d, 2H, J = 8.0 Hz, Ar), 8.17 (broad s, 
1H, NH), 8.51 (broad s, 1H, NH); 
13
C NMR (DMSO–d6): δ 115.5, 119.3, 122.2, 122.7, 
129.9, 130.1, 141.5, 145.4 (Ar), 154.3 (CO). 
 
4-(tert-butoxycarbonylamino)benzamide (22c). Aniline (930 mg, 10 mmol) and 
TBTU (3.211 g, 10 mmol) were added at 0 °C and under argon over a solution 
containing 4-[(tert-butoxycarbonyl)amino]benzoic acid (2.373 g, 10.0 mmol) and Et3N 
(5.6 mL, 40 mmol) in 15 mL of dry CH2Cl2. The reaction mixture was stirred at room 
temperature for 7 hours. After that time a white precipitate was formed. This precipitate 
turned out to be the desired compound and was filtered and washed with cold hexane to 
yield 2.3 g (74%) of 4-(tert-butoxycarbonylamino)benzamide as a white solid; mp 205–
207 °C; IR (nujol) ν 3352, 3330 (NH), 1704, 1646 (CO) cm-1. 1H NMR (DMSO–d6): δ 
1.51 (s, 9H, (CH3)3), 7.06–7.15 (m, 1H, Ar), 7.32–7.42 (m, 2H, Ar), 7.54–7.67 (m, 2H, 
Ar), 7.74–7.85 (m, 2H, Ar), 7.89–7.99 (m, 2H, Ar), 9.72 (broad s, 1H, NH), 10.09 
(broad s, 1H, NH); 
13
C NMR (DMSO–d6): δ 29.4 ((CH3)3), 80.9 (C(CH3)3), 118.5, 
121.7, 124.8, 129.4, 129.9, 130.0, 140.7, 144.1 (Ar), 154.0 ((CH3)3COCO), 166.3 
(PhNHCOPh).  
 
4-aminobenzanilide (22). A solution of 3.113 g (10.0 mmol) of 22c in 35 mL of 
CH2Cl2:TFA (1:1) was stirred at room temperature for 6 h. After that time, the solvent 
was eliminated under vacuum to generate the trifluoroacetate salt. This salt was 
redissolved in 20 mL of CH2Cl2 and was washed with a 2M NaOH solution (2 × 15 
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mL). The organic layer was dried over anhydrous Na2SO4, filtered and the solvent was 
evaporated to afford 1.961 g (93%) of 4-aminobenzanilide
 
as a white solid; mp 136–138 
°C (Lit.
49
: 138–140 ºC); IR (nujol) ν 3393, 3350, 3184 (NH, NH2), 1644 (CO) cm
-1
; 
1
H 
NMR (DMSO–d6)
50
: δ 5.79 (broad s, 2H, NH2), 6.64 (d, 2H, J = 8.8 Hz, Ar), 7.02–7.11 
(m, 1H, Ar), 7.31–7.40 (m, 2H, Ar), 7.72–7.86 (m, 4H, Ar), 9.80 (broad s, 1H, NH); 
13
C 
NMR (DMSO–d6): δ 113.9, 121.5, 122.4, 124.2, 129.8, 130.7, 141.1, 153.5 (Ar), 166.7 
(CO). 
 
2) Synthesis of Boc-protected precursors and new tested compounds.  
A. General method for the synthesis of the Boc-protected guanidine and Boc-
protected 2-aminoimidazoline precursors: 6.6 mmol of HgCl2 were added over a 
solution of 3.0 mmol of the corresponding diamine, 6.0 mmol of N,N’-di(tert-
butoxycarbonyl)thiourea (for 7d, 9d, and 11d) or N,N’-di(tert-
butoxycarbonyl)imidazolidine-2-thione (for 7e, 9e, and 11e) and 2.1 mL (15.0 mmol) of 
Et3N in DMF (10 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and for 
the appropriate duration at room temperature. Then, the reaction mixture was diluted 
with EtOAc and filtered through a pad of Celite. The filter cake was rinsed with EtOAc. 
The organic phase was extracted with water (2 × 30 mL), washed with brine (1 × 30 
mL), dried over anhydrous Na2SO4 and concentrated under vacuum to give a residue 
that was purified by column chromatography as specified.  
 
B. General method for the removal of the Boc-protecting groups and 
regeneration of the hydrochloride salts. A solution of the corresponding Boc-
protected derivative (0.5 mmol) in 20 mL of CH2Cl2:TFA (1:1) was stirred at room 
temperature for the appropriate duration. After that time, the solvent was eliminated 
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under vacuum to generate the trifluoroacetate salt. This salt was dissolved in 20 mL of 
water and treated for 24 h with IRA400 Amberlyte resin in its Cl
-
 form. Then, the resin 
was removed by filtration and the aqueous solution washed with CH2Cl2 (2 × 10 mL). 
Evaporation of the water afforded the pure dihydrochloride salt as a hygroscopic solid. 
Absence of the trifluoroacetate salt was checked by 
19
F NMR. 
 
C. Alternative method for the synthesis of the Boc-protected guanidines 20d, 21d 
and 23d. A solution of 4-[2,3-di(tert-butoxycarbonyl)guanidino]aniline 8 in dry CH2Cl2 
was treated under an inert atmosphere and at 0 °C with the corresponding electrophile 
(phenyl isocyanate for 20d, phenyl isothiocyanate for 21d and benzoyl chloride for 23d) 
and with Et3N (only in the case of 23d). After allowing the reaction mixture to reach 
room temperature it was stirred for the appropriate duration. Further work up followed 
by column cromatography as specified afforded the corresponding Boc-protected 
guanidine. 
 
1,3-Bis(4-[2,3-di(tert-butoxycarbonyl)guanidino]phenyl)urea (7d). Following the 
general synthetic method A, the crude residue was purified by silica gel column 
chromatography, eluting with hexane:EtOAc (3:1) to yield 1.24 g (57%) of 7d as a 
white solid; mp > 300 °C; MS (ESI
+
) m/z 727.3777 [M+H]
+
; IR (nujol) ν 3368, 3307, 
3264 (NH), 1720, 1644, 1624, 1605 (CO, CN) cm
-1
; 
1
H NMR (CDCl3): δ 1.46 (s, 18H, 
(CH3)3), 1.58 (s, 18H, (CH3)3), 7.25 (d, 4H, J = 8.5 Hz, Ar), 7.29 (d, 4H, J = 8.5 Hz, 
Ar), 7.40 (broad s, 2H, NHCONH), 10.14 (broad s, 2H, NHGu), 11.64 (broad s, 2H, 
NHGu); 
13
C NMR (CDCl3): δ 28.0, 28.1 ((CH3)3), 80.0, 83.8 (C(CH3)3), 118.8, 124.8, 
129.9, 137.6 (Ar), 152.1, 153.1 ((CH3)3COCO), 155.3, 163.2 (NHCONH, CN). 
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1,3-Bis(4-[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]phenyl)urea (7e). 
Following the general synthetic method A. The crude residue was purified by neutral 
alumina column flash chromatography, eluting with CH2Cl2:EtOAc (1:5). The residue 
obtained after the column was precipitated with cold hexane to yield 1.25 g (63%) of 7e 
as a white solid; mp 180–182 °C; IR (nujol) ν 3357 (NH), 1757, 1704, 1648 (CO, CN) 
cm
-1
; 
1
H NMR (CDCl3): δ 1.33 (s, 36H, (CH3)3), 3.83 (s, 8H, CH2), 6.90 (d, 4H, J = 7.0 
Hz, Ar), 7.14–7.26 (m, 6H, 4Ar + 2NH); 
13
C NMR (CDCl3): δ 27.8 ((CH3)3), 43.1 
(CH2), 82.9 (C(CH3)3), 120.6, 121.8, 133.9, 139.3 (Ar), 143.4 ((CH3)3COCO), 150.2, 
153.5 (NHCONH, CN). 
 
Dihydrochloride salt of 1,3-bis(4-guanidinophenyl)urea (7a). Following the 
general method B, 210 mg (95%) of the pure dihydrochloride salt of 7a were obtained 
as a white solid; mp decomposes over 248 °C; MS (ESI
+
) m/z 327.1928 [M+H]
+
; 
1
H 
NMR (D2O): δ 7.27 (d, 4H, J = 8.5 Hz, Ar), 7.43 (d, 4H, J = 8.5 Hz, Ar); 13C NMR 
(D2O): δ 121.6, 126.4, 129.1, 137.0 (Ar), 155.0, 156.0 (CO, CN); Anal. 
(C15H20Cl2N8O
.
2.3H2O) C, H, N.  
 
1,3-Bis(4-[2,3-di(tert-butoxycarbonyl)guanidino]phenyl)thiourea (8d). A solution 
of 701 mg (2.0 mmol) of 4-[2,3-di(tert-butoxycarbonyl)guanidino]aniline 8 and carbon 
disulfide 3.0 mL (50.0 mmol) in 20 mL of CH2Cl2 was stirred at reflux for 54 h. 
Afterwards, the solvent was evaporated to give a residue that was purified by silica gel 
column chromatography, eluting with hexane:EtOAc (3:2) to yield 240 mg (32%) of 8d 
as a white solid; mp > 300 °C; MS (ESI
+
) m/z 743.3412 [M+H]
+
; IR (nujol) ν 3396, 
3291, 3169 (NH), 1720, 1646, 1630, 1152 (CO, CN, CS) cm
-1
; 
1
H NMR (CDCl3): δ 
1.50 (s, 18H, (CH3)3), 1.55 (s, 18H, (CH3)3), 7.34 (d, 4H, J = 8.0 Hz, Ar), 7.61 (d, 4H, 
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J = 8.0 Hz, Ar), 7.98 (broad s, 2H, NHCSNH), 10.36 (broad s, 2H, NHGu), 11.63 (broad 
s, 2H, NHGu); 
13
C NMR (CDCl3): δ 27.8, 27.9 ((CH3)3), 79.6, 83.6 (C(CH3)3), 123.4, 
124.9, 134.0, 134.8 (Ar), 152.9, 153.8 (CO), 163.1 (CN), 179.4 (CS). 
 
4,4’-Bis[2,3-di(tert-butoxycarbonyl)guanidino]benzanilide (9d). Following the 
general synthetic method A. The crude residue was purified by silica gel column 
chromatography, eluting with hexane:EtOAc (2:1) to yield 1.3 g (61%) of 9d as a white 
solid; mp > 300 °C; MS (ESI
+
) m/z 712.3635 [M+H]
+
; IR (nujol) ν 3368, 3291, 3261 
(NH), 1738, 1720, 1645, 1627, 1608 (CO, CN) cm
-1
; 
1
H NMR (CDCl3): δ 1.48 (s, 9H, 
(CH3)3), 1.51 (s, 9H, (CH3)3), 1.56 (s, 18H, (CH3)3), 7.54 (d, 2H, J = 8.6 Hz, Ar), 7.64 
(d, 2H, J = 8.0 Hz, Ar), 7.68 (d, 2H, J = 8.0 Hz, Ar), 7.82 (d, 2H, J = 8.6 Hz, Ar), 8.19 
(broad s, 1H, PhNHCOPh), 10.30 (broad s, 1H, NHGu), 10.51 (broad s, 1H, NHGu), 
11.63 (broad s, 2H, NHGu); 
13
C NMR (CDCl3): δ 27.9, 28.0 ((CH3)3), 79.6, 80.0, 83.6, 
84.0 (C(CH3)3), 120.6, 122.1, 123.4, 128.1, 131.2, 132.1, 135.9, 139.3 (Ar), 153.2, 
153.7, 154.0 ((CH3)3COCO), 163.1, 163.4 (CN), 165.2 (PhNHCOPh). 
 
4,4’-Bis[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]benzanilide (9e). 
Following the general synthetic method A, the crude residue was purified by neutral 
alumina column flash chromatography, eluting with hexane:EtOAc (1:4). The residue 
obtained after the column was recrystallised from Et2O to yield 1.040 g (45%) of 9e as a 
white solid; mp 198–200 °C; IR (nujol) ν 3346 (NH), 1733, 1709, 1689, 1663, 1598 
(CO, CN) cm
-1
; 
1
H NMR (DMSO–d6): δ 1.30 (s, 36H, (CH3)3), 3.77 (s, 4H, CH2), 3.80 
(s, 4H, CH2), 6.83 (d, 2H, J = 8.5 Hz, Ar), 6.92 (d, 2H, J = 8.5 Hz, Ar), 7.66 (d, 2H, J = 
8.5 Hz, Ar), 7.89 (d, 2H, J = 8.5 Hz, Ar), 9.92 (broad s, 1H, NH); 
13
C NMR (DMSO–
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d6): δ 28.4, 28.5 ((CH3)3), 43.9, 44.0 (CH2), 82.4, 82.6 (C(CH3)3), 121.3, 121.6, 121.7, 
128.6, 129.3, 134.8, 139.8, 141.0 (Ar), 145.1, 150.4, 150.6, 152.9 ((CH3)3COCO), CN), 
165.4 (PhNHCOPh).  
 
1,4-Bis[4-(N
2
,N
3
-bis(tert-butyloxycarbonyl)guanidino)phenyl]piperidine (11d). 
General method A with 598 mg (2.2 mmol) of HgCl2, 268 mg (1.0 mmol) of 11, 553 
mg (2.0 mmol) of N,N’-di(tert-butoxycarbonyl)thiourea and 0.9 mL (6.4 mmol) of Et3N 
in CH2Cl2:DMF (1:2) (8 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h 
and 36 h more at room temperature. After general workup, the residue was purified by 
silica gel column chromatography, eluting with hexane:EtOAc (3:1) to yield 483 mg 
(64%) of 11d as a white solid; mp decomposes over 220 °C; MS (ESI
+
) m/z 752.4326 
[M+H]
+
; IR (nujol) ν 3291, 3266 (NH), 1728, 1638, 1608 (CO, CN) cm-1; 1H NMR 
(CDCl3): δ 1.52 (s, 18H, (CH3)3), 1.55 (s, 18H, (CH3)3), 1.82–2.00 (m, 4H, H3Pip.), 
2.56–2.69 (m, 1H, H4Pip.), 2.71–2.89 (m, 2H, H2ePip.), 3.71–3.82 (m, 2H, H2aPip.), 
6.95 (d, 2H, J = 8.0 Hz, Ar), 7.22 (d, 2H, J = 7.0 Hz, Ar), 7.48 (d, 2H, J = 8.0 Hz, Ar), 
7.54 (d, 2H, J = 7.0 Hz, Ar), 10.19 (broad s, 1H, NH), 10.29 (broad s, 1H, NH), 11.68 
(broad s, 2H, NH); 
13
C NMR (CDCl3): δ 28.0, 28.1, 28.2 ((CH3)3), 33.1 (C3Pip.), 41.8 
(C4Pip.), 50.8 (C2Pip.), 79.3, 79.4, 83.3, 83.5 (C(CH3)3), 117.0, 122.4, 123.3, 127.2, 
128.7, 134.7, 142.5, 149.0 (Ar), 153.2, 153.3, 153.4, 153.5 (CO), 163.5, 163.6 (CN).  
 
Di-tert-butyl-2-(4-[4-(4-[1,3-bis(tert-butyloxycarbonyl)-tetrahydro-1H-2-
imidazolyliden]aminophenyl)piperidino]phenylimino)-1,3-
imidazolidinedicarboxylate (11e). Method A with 598 mg (2.2 mmol) of HgCl2, 268 
mg (1.0 mmol) of 11, 605 mg (2.0 mmol) of N,N’-di(tert-
butoxycarbonyl)imidazolidine-2-thione and 0.9 mL (6.4 mmol) of Et3N in CH2Cl2:DMF 
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(1:2) (8 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and 41 h more at 
room temperature. The reaction was worked up and purified by silica gel column 
chromatography, eluting with hexane:EtOAc (1:1). The residue obtained after the 
column was recrystallised from hexane:Et2O (1:1) to yield 523 mg (65%) of 11e as a 
white solid; mp 191–193 °C; MS (ESI
+
) m/z 804.4681 [M+H]
+
; IR (nujol) ν 1753, 1704, 
1662, 1606 (CO, CN) cm
-1
; 
1
H NMR (CDCl3): δ 1.32 (s, 18H, (CH3)3), 1.34 (s, 18H, 
(CH3)3), 1.83–1.98 (m, 4H, H3Pip.), 2.49–2.61 (m, 1H, H4Pip.), 2.66–2.79 (m, 2H, 
H2ePip.), 3.60–3.71 (m, 2H, H2aPip.), 3.83 (s, 8H, CH2), 6.85–7.0 (m, 6H, Ar), 7.11 (d, 
2H, J = 8.0 Hz, Ar); 
13
C NMR (CDCl3): δ 27.8, 27.9 ((CH3)3), 33.4 (C3Pip.), 41.8 
(C4Pip.), 43.0 (CH2), 51.8 (C2Pip.), 82.5, 82.7 (C(CH3)3), 117.8, 121.4, 122.2, 126.9, 
138.4, 139.0, 140.4, 141.1 (Ar), 146.4, 148.0 (CO); 150.3, 150.4 (CN). 
 
Trihydrochloride salt of 1,4-bis(4-guanidinophenyl)piperidine (11a). Following 
method B, 224 mg (90%) of the pure hydrochloride salt of 11a were obtained as a 
brown solid; mp = decomposes over 220 °C; 
1
H NMR (D2O): δ 2.19–2.33 (m, 4H, 
H3Pip.), 3.10–3.24 (m, 1H, H4Pip.), 3.80–3.93 (m, 4H, H2Pip.), 7.32 (d, 2H, J = 8.0 Hz, 
Ar), 7.48 (d, 2H, J = 8.0 Hz, Ar), 7.54 (d, 2H, J = 8.5 Hz, Ar), 7.78 (d, 2H, J = 8.5 Hz, 
Ar); 
13
C NMR (D2O): δ 29.9 (C3Pip.), 37.4 (C4Pip.), 56.3 (C2Pip.), 122.3, 125.8, 126.6, 
127.8, 132.3, 135.9, 139.4, 142.9 (Ar), 155.6, 155.9 (CN). Anal. (C19H28Cl3N7
.
2 H2O) 
C, H, N. 
Trihydrochloride salt of 1,4-bis[4-(4,5-dihydro-1H-2-
imidazolylamino)phenyl]piperidine (11b). Following method B, 279 mg (94%) of the 
pure hydrochloride salt of 11b were obtained as a brown solid; mp 101–103 °C; MS 
(ESI
+
) m/z 404.2578 [M+H]
+
; 
1
H NMR (D2O): δ 2.14–2.29 (m, 4H, H3Pip.), 3.07–3.19 
(m, 1H, H4Pip.), 3.72 (s, 4H, CH2), 3.76 (s, 4H, CH2), 3.74–3.86 (m, 4H, H2Pip.), 7.26 
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(d, 2H, J = 8.6 Hz, Ar), 7.43 (d, 2H, J = 8.0 Hz, Ar), 7.49 (d, 2H, J = 8.6 Hz, Ar), 7.75 
(d, 2H, J = 8.0 Hz, Ar); 
13
C NMR (D2O): δ 29.8 (C3Pip.), 37.3 (C4Pip.), 42.2, 42.3 
(CH2), 56.3 (C2Pip.), 122.2, 124.0, 125.0, 127.7, 133.2, 136.5, 138.9, 142.3 (Ar), 157.8, 
158.2 (CN); Anal. (C23H32Cl3N7
.
2.3H2O) C, H, N.  
4-[2,3-di(tert-butoxycarbonyl)guanidino]benzophenone (19d). Method A with 896 
mg (3.3 mmol) of HgCl2, 592 mg (3.0 mmol) of 4-aminobenzophenone, 830 mg (3.0 
mmol) of N,N’-di(tert-butoxycarbonyl)thiourea and 1.3 mL (9.3 mmol) of Et3N in DMF 
(5 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and 48 h more at room 
temperature. The reaction was worked up and purified by silica gel column 
chromatography, eluting with hexane:EtOAc (2:1) to yield 976 mg (74%) of 19d as a 
white solid; mp 151–153 °C; IR (nujol) ν 3197, 3154 (NH), 1718, 1656, 1643, 1595 
(CO, CN) cm
-1
; 
1
H NMR (CDCl3): δ 1.53 (s, 9H, (CH3)3), 1.56 (s, 9H, (CH3)3), 7.44–
7.51 (m, 2H, Ar), 7.54–7.60 (m, 1H, Ar), 7.75–7.86 (m, 6H, Ar), 10.63 (broad s, 1H, 
NH), 11.66 (broad s, 1H, NH); 
13
C NMR (CDCl3): δ 28.0, 28.1 ((CH3)3), 80.0, 84.1 
(C(CH3)3), 120.9, 128.1, 129.8, 131.3, 132.1, 133.2, 137.8, 140.8 (Ar), 153.1, 153.2 
((CH3)3COCO), 163.2 (CN), 195.6 (PhCOPh). 
 
4-[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]benzophenone (19e). 
Method A with 896 mg (3.3 mmol) of HgCl2, 592 mg (3.0 mmol) of 4-
aminobenzophenone, 907 mg (3.0 mmol) of N,N’-di(tert-butoxycarbonyl)imidazolidine-
2-thione and 1.3 mL (9.3 mmol) of Et3N in DMF (5 mL). The resulting mixture was 
stirred at 0 °C for 1 h and 48 h more at room temperature. The reaction was worked up 
and purified by neutral alumina column flash chromatography, eluting with hexane: 
EtOAc (2:3). The residue obtained after the column was precipitated and washed with 
cold hexane: Et2O (1:1) to yield 600 mg (43%) of 19e as a white solid; mp 49–51 °C; IR 
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(nujol) ν 1750, 1719, 1644 (CO, CN) cm-1; 1H NMR (CDCl3): δ 1.28 (s, 18H, (CH3)3), 
3.78 (s, 4H, CH2), 6.96 (d, 2H, J = 8.5 Hz, Ar), 7.33–7.39 (m, 2H, Ar), 7.41–7.48 (m, 
1H, Ar), 7.61–7.70 (m, 4H, Ar); 
13
C NMR (CDCl3): δ 27.5 ((CH3)3), 42.9 (CH2), 82.6 
(C(CH3)3), 120.6, 127.7, 129.2, 130.7, 131.1, 131.4, 138.1, 140.1 (Ar), 149.5 
((CH3)3COCO), 152.9 (CN), 195.4 (PhCOPh).  
 
Hydrochloride salt of 4-guanidinobenzophenone (19a). Following method B, 145 
mg (97%) of the pure hydrochloride salt of 19a was obtained as a white solid; mp 187–
189 °C; MS (ESI
+
) m/z 240.1208 [M+H]
+
; 
1
H NMR (D2O): δ 7.15 (d, 2H, J = 8.0 Hz, 
Ar), 7.23–7.31 (m, 2H, Ar), 7.40 (d, 2H, J = 8.0 Hz, Ar), 7.44–7.52 (m, 3H, Ar); 
13
C 
NMR (D2O): δ 122.7, 127.9, 129.5, 131.4, 132.9, 133.7, 135.6, 138.7 (Ar), 154.9 (CN), 
197.6 (CO). 
 
Hydrochloride salt of 4-(2-imidazolidinylimino)benzophenone (19b). Following 
method B, 156 mg (92%) of the pure hydrochloride salt of 19b were obtained as a 
yellow solid; mp 64–66 °C; MS (ESI
+
) m/z 266.1324 [M+H]
+
; 
1
H NMR (D2O): δ 3.64 
(s, 4H, CH2), 7.01 (d, 2H, J = 8.8 Hz, Ar), 7.18–7.25 (m, 2H, Ar), 7.31 (d, 2H, J = 7.2 
Hz, Ar), 7.34–7.43 (m, 3H, Ar); 
13
C NMR (D2O): δ 42.2 (CH2), 120.7, 127.9, 129.4, 
131.4, 132.8, 133.0, 135.5, 139.2 (Ar), 156.5 (CN), 197.1 (CO); Anal. Calc. 
(C16H16ClN3O
.
2.0H2O) C, H, N.  
 
1-(4-[2,3-di(tert-butoxycarbonyl)guanidino]phenyl)-3-phenylurea (20d). Method 
A with 896 mg (3.3 mmol) of HgCl2, 682 mg (3.0 mmol) of 1-(4-aminophenyl)-3-
phenylurea 20, 830 mg (3.0 mmol) of N,N’-di(tert-butoxycarbonyl)thiourea and 1.3 mL 
(9.3 mmol) of Et3N in DMF (6 mL) at 0 °C. The resulting mixture was stirred at 0 °C 
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for 1 h and 26 h more at room temperature. Then, the reaction mixture was diluted with 
EtOAc and filtered through a pad of Celite. The filter cake was rinsed with EtOAc. The 
organic phase was extracted with water (2 × 30 mL), washed with brine (1 × 30 mL), 
dried over anhydrous Na2SO4 and concentrated under vacuum to give a residue that was 
purified by silica gel column chromatography, eluting with hexane:EtOAc (1:1) to yield 
940 mg (67%) of 20d as a white solid.  
Method C: 0.33 mL (3.0 mmol) of phenyl isocyanate were added under an inert 
atmosphere and at 0 °C over a solution of 1.052 g (3.0 mmol) of 4-[2,3-di(tert-
butoxycarbonyl)guanidino]aniline 8 in dry CH2Cl2 (10 mL). The mixture was allowed 
to reach room temperature and was stirred for 10 h. Then, the solvent was removed in 
vacuo and the residue obtained was purified by silica gel column chromatography, 
eluting with hexane:EtOAc (1:1). The pure compound 20d was obtained as a white 
solid (1.034 g, 73%) by recrystallization from hexane:CH2Cl2; mp > 300 °C; MS (ESI
+
) 
m/z 470.2425 [M+H]
+
; IR (nujol) ν 3300 (NH), 1726, 1633, 1600, 1568 (CO, CN) cm-1; 
1
H NMR (DMSO–d6): δ 1.42 (s, 9H, (CH3)3), 1.53 (s, 9H, (CH3)3), 6.94–7.02 (m, 1H, 
Ar), 7.24–7.33 (m, 2H, Ar), 7.38–7.53 (m, 6H, Ar), 8.69 (broad s, 1H, NHCONH), 8.71 
(broad s, 1H, NHCONH), 9.96 (broad s, 1H, NHGu), 11.54 (broad s, 1H, NHGu); 
13
C 
NMR (DMSO–d6): δ 28.9, 29.2 ((CH3)3), 80.0, 84.6 (C(CH3)3), 119.5, 119.6, 123.1, 
125.1, 130.1, 131.8, 138.2, 141.0 (Ar), 153.6, 153.8, 154.5, 164.2 ((CH3)3COCO, CN, 
NHCONH). 
 
1-(4-[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]phenyl)-3-phenylurea 
(20e). Method A with 896 mg (3.3 mmol) of HgCl2, 682 mg (3.0 mmol) of 20, 907 mg 
(3.0 mmol) of N,N’-di(tert-butoxycarbonyl)imidazolidine-2-thione and 1.3 mL (9.3 
mmol) of Et3N in DMF (6 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h 
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and 38 h more at room temperature. Then, the reaction mixture was diluted with EtOAc 
and filtered through a pad of Celite. The filter cake was rinsed with EtOAc. The organic 
phase was extracted with water (2 ×30 mL), washed with brine (1 × 30 mL), dried over 
anhydrous Na2SO4 and concentrated under vacuum to give a residue that was purified 
by neutral alumina column flash chromatography, eluting with hexane:EtOAc:CH2Cl2 
(6:4:1) to yield 924 mg (62%) of 20e as a white solid; mp 162–164 °C; IR (nujol) ν 
3365 (NH), 1739, 1728, 1708, 1694 (CO, CN) cm
-1
; 
1
H NMR (DMSO–d6): δ 1.29 (s, 
18H, (CH3)3), 3.75 (s, 4H, CH2), 6.79 (d, 2H, J = 7.0 Hz, Ar), 6.92–7.01 (m, 1H, Ar), 
7.23–7.36 (m, 4H, Ar), 7.45 (d, 2H, J = 7.5 Hz, Ar), 8.51 (broad s, 1H, NH), 8.57 
(broad s, 1H, NH); 
13
C NMR (DMSO–d6): δ 28.8 ((CH3)3), 44.2 (CH2), 82.7 
(C(CH3)3), 119.4, 120.0, 122.5, 122.9, 130.1, 135.5, 140.0, 141.2 (Ar), 144.3, 151.0, 
153.8 ((CH3)3COCO, CN, NHCONH). 
 
Trifluoroacetate salt of 1-(4-guanidinophenyl)-3-phenylurea (20a). A solution of 
235 mg (0.5 mmol) of 20d in 20 mL of CH2Cl2:TFA (1:1) was stirred at room 
temperature for 3 h. After that time, the solvent was eliminated under vacuum and cold 
water was added to generate a precipitate that was filtered, washed with 100 more mL 
of cold water and dried to yield 176 mg (91%) of the pure trifluoroacetate salt as a 
purple solid; mp 116–118 °C; MS (ESI
+
) m/z 270.1328 [M+H]
+
; 
1
H NMR (CD3OD): δ 
6.96–7.03 (m, 1H, Ar), 7.18 (d, 2H, J = 8.5 Hz, Ar), 7.23–7.31 (m, 2H, Ar), 7.36–7.45 
(m, 2H, Ar), 7.43 (d, 2H, J = 8.0 Hz, Ar); 
13
C NMR (CD3OD): δ 120.5, 121.4, 123.8, 
124.0, 127.7, 129.8, 140.3, 140.4 (Ar), 155.3, 158.3 (CN, CO); 
19
F NMR (CD3OD): δ -
79.35; Anal. (C16H16F3N5O3
.
0.2H2O) C, H, N.  
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Trifluoroacetate salt of 1-[4-(2-imidazolidinylimino)phenyl]-3-phenylurea (20b). 
A solution of 248 mg (0.5 mmol) of 20e in 20 mL of CH2Cl2:TFA (1:1) was stirred at 
room temperature for 3 h. After that time, the solvent was eliminated under vacuum and 
cold water was added to generate a precipitate that was filtered, washed with 100 more 
mL of cold water and dried to yield 194 mg (89%) of the pure trifluoroacetate salt as a 
grey solid; mp 102–104 °C; MS (ESI
+
) m/z 296.1522 [M+H]
+
; 
1
H NMR (CD3OD): δ 
3.73 (s, 4H, CH2), 6.96–7.04 (m, 1H, Ar), 7.18 (d, 2H, J = 9.0 Hz, Ar), 7.22–7.30 (m, 
2H, Ar), 7.44 (d, 2H, J = 7.6 Hz, Ar), 7.53 (d, 2H, J = 9.0 Hz, Ar); 
13
C NMR (CD3OD): 
δ 44.1 (CH2), 120.5, 121.2, 124.0, 126.3, 129.8, 130.9, 140.1, 140.3 (Ar), 155.3, 160.4 
(CN, CO); 
19
F NMR (CD3OD): δ -78.90; Anal. (C18H18F3N5O3.1.4H2O) C, H, N.  
 
1-(4-[2,3-di(tert-butoxycarbonyl)guanidino]phenyl)-3-phenylthiourea (21d). 
Method C with 0.37 mL (3.0 mmol) of phenyl isothiocyanate and 1.052 g (3.0 mmol) 
of 4-[2,3-di(tert-butoxycarbonyl)guanidine]aniline 8 in dry CH2Cl2 (10 mL). The 
mixture was allowed to reach room temperature and was stirred for 18 h. Then, the 
solvent was removed in vacuo and the residue obtained was purified by silica gel 
column chromatography, eluting with hexane:EtOAc (1:1). The pure compound, 21d, 
was obtained as a white solid (988 mg, 68%) by recrystallization from hexane: CH2Cl2; 
mp 120–122 °C; MS (ESI
+
) m/z 486.2248 [M+H]
+
; IR (nujol) ν 3291, 3247, 3165, 3099 
(NH), 1717, 1644, 1599, 1150 (CO, CN, CS) cm
-1
; 
1
H NMR (DMSO–d6): δ 1.43 (s, 9H, 
(CH3)3), 1.54 (s, 9H, (CH3)3), 7.09–7.17 (m, 1H, Ar), 7.29–7.40 (m, 2H, Ar), 7.43–7.62 
(m, 6H, Ar), 9.82 (broad s, 1H, NHCSNH), 9.83 (broad s, 1H, NHCSNH), 10.02 (broad 
s, 1H, NHGu), 11.50 (broad s, 1H, NHGu); 
13
C NMR (DMSO–d6): δ 29.0, 29.2 ((CH3)3), 
80.1, 84.7 (C(CH3)3), 124.2, 124.9, 125.2, 125.7, 129.7, 134.2, 137.6, 140.8 (Ar), 
153.5, 154.2 (CO), 164.1 (CN), 180.8 (CS). 
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1-(4-[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]phenyl)-3-
phenylthiourea (21e). 896 mg (3.3 mmol) of HgCl2 were added over a solution of 325 
mg (3.0 mmol) of 1,4-phenylenediamine, 907 mg (3.0 mmol) of N,N’-di(tert-
butoxycarbonyl)imidazolidine-2-thione and 1.3 mL (9.3 mmol) of Et3N in DMF (5 mL) 
at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and 22 h more at room 
temperature. Then, the reaction mixture was diluted with EtOAc and filtered through a 
pad of Celite. The filter cake was rinsed with EtOAc. The organic phase was extracted 
with water (2 × 30 mL), washed with brine (1 × 30 mL), dried over anhydrous Na2SO4 
and concentrated under vacuum to give a dark residue. This residue was dissolved in 10 
mL of dry CH2Cl2 and 0.37 mL (3.0 mmol) of phenyl isothiocyanate were added under 
an inert atmosphere and at 0 °C. The mixture was allowed to reach room temperature 
and was stirred for 19 h. Then, the solvent was removed in vacuo and the new residue 
obtained was purified by neutral alumina column flash chromatography, eluting with 
hexane:EtOAc (3:7) to yield 347 mg (22%) of 21e as a white solid; mp 118–120 °C; IR 
(nujol) ν 3311 (NH), 1756, 1716, 1151 (CO, CN, CS) cm-1; 1H NMR (CDCl3): δ 1.34 
(s, 18H, (CH3)3), 3.82 (s, 4H, CH2), 6.99 (d, 2H, J = 8.0 Hz, Ar), 7.16–7.25 (m, 3H, 
Ar), 7.30–7.42 (m, 4H, Ar), 7.89 (broad s, 1H, NH), 8.16 (broad s, 1H, NH); 
13
C NMR 
(CDCl3): δ 27.8 ((CH3)3), 43.1 (CH2), 82.9 (C(CH3)3), 122.2, 124.7, 125.9, 126.1, 
128.8, 130.8, 137.8, 140.0 (Ar), 147.5, 149.8 (CO, CN), 179.8 (CS). 
 
Trifluoroacetate salt of 1-(4-guanidinophenyl)-3-phenylthiourea (21a). A solution 
of 243 mg (0.5 mmol) of 21d in 20 mL of CH2Cl2:TFA (1:1) was stirred at room 
temperature for 3 h. After that time, the solvent was eliminated under vacuum and cold 
water was added to generate a precipitate that was filtered, washed with 100 more mL 
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of cold water and dried to yield 197 mg (94%) of the pure trifluoroacetate salt as a white 
solid; mp 166–168 °C; MS (ESI
+
) m/z 286.1183 [M+H]
+
; 
1
H NMR (CD3OD): δ 7.16–
7.28 (m, 3H, Ar), 7.31–7.47 (m, 4H, Ar), 7.53 (d, 2H, J = 7.5 Hz, Ar); 
13
C NMR 
(CD3OD): δ 122.4, 123.6, 124.2, 124.6, 126.6, 129.9, 136.5, 136.9 (Ar), 158.4 (CN), 
182.4 (CS); 
19
F NMR (CD3OD): δ -78.97; Anal. (C16H16F3N5O2S.1.0H2O) C, H, N.  
Trifluoroacetate salt of 1-[4-(2-imidazolidinylimino)phenyl]-3-phenylthiourea 
(21b). A solution of 256 mg (0.5 mmol) of 21e in 20 mL of CH2Cl2:TFA (1:1) was 
stirred at room temperature for 3 h. After that time, the solvent was eliminated under 
vacuum and cold water was added to generate a precipitate that was filtered, washed 
with 100 more mL of cold water and dried to yield 221 mg (92%) of the pure 
trifluoroacetate salt as a yellow solid; mp 138–140 °C; MS (ESI
+
) m/z 312.1379 
[M+H]
+
; 
1
H NMR (D2O): δ 3.72 (s, 4H, CH2), 7.26–7.40 (m, 7H, Ar), 7.41–7.48 (m, 
2H, Ar); 
13
C NMR (D2O): δ 42.2 (CH2), 124.7, 125.8, 127.1, 127.4, 129.1, 133.3, 136.3, 
136.6 (Ar), 158.2 (CN), 179.4 (CS); 
19
F NMR (D2O): δ -76.15; Anal. 
(C18H18F3N5O2S
.
3.0H2O) C, H, N.  
 
4-[2,3-di(tert-butoxycarbonyl)guanidino]benzanilide (22d). Method A with 896 
mg (3.3 mmol) of HgCl2, 637 mg (3.0 mmol) of 4-aminobenzanilide, 830 mg (3.0 
mmol) of N,N’-di(tert-butoxycarbonyl)thiourea and 1.3 mL (9.3 mmol) of Et3N in 
CH2Cl2:DMF (5:1) (6 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and 
22 h more at room temperature. The reaction was worked up and purified by silica gel 
column chromatography, eluting with hexane:EtOAc (2:1) to yield 1.015 g (74%) of 
22d as a white solid; mp > 300 °C; MS (ESI
+
) m/z 477.2269 [M+Na]
+
; IR (nujol, cm
-1
) 
ν 3375, 3187 (NH), 1718, 1658, 1643, 1596 (CO, CN); 1H NMR (CDCl3): δ 1.54 (s, 
9H, (CH3)3), 1.57 (s, 9H, (CH3)3), 7.11–7.20 (m, 1H, Ar), 7.33–7.42 (m, 2H, Ar), 7.63–
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7.78 (m, 4H, Ar), 7.80–7.93 (m, 2H, Ar), 8.08 (broad s, 1H, PhNHCOPh), 10.55 (broad 
s, 1H, NHGu), 11.65 (broad s, 1H, NHGu); 
13
C NMR (CDCl3): δ 27.9, 28.0 ((CH3)3), 
80.1, 84.1 (C(CH3)3), 120.1, 122.4, 124.1, 128.0, 128.8, 131.3, 138.4, 139.3 (Ar), 
153.1, 153.8 ((CH3)3COCO), 163.1 (CN), 165.6 (PhNHCOPh). 
 
4-[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]benzanilide (22e). Method 
A with 896 mg (3.3 mmol) of HgCl2, 637 mg (3.0 mmol) of 4-aminobenzanilide, 907 
mg (3.0 mmol) of N,N’-di(tert-butoxycarbonyl)imidazolidine-2-thione and 1.3 mL (9.3 
mmol) of Et3N in CH2Cl2:DMF (5:1) (6 mL) at 0 °C. The resulting mixture was stirred 
at 0 °C for 1 h and 25 h more at room temperature. The reaction was worked up and 
purified by neutral alumina column flash chromatography, eluting with hexane:EtOAc 
(6:4). The residue obtained after the column was recrystallised from hexane:Et2O (1:1) 
to yield 843 mg (58%) of 22e as a white solid; mp 163–165 °C; IR (nujol) ν 3338 (NH), 
1737, 1707, 1670, 1637 (CO, CN) cm
-1
; 
1
H NMR (CDCl3): δ 1.34 (s, 18H, (CH3)3), 
3.85 (s, 4H, CH2), 7.03 (d, 2H, J = 8.5 Hz, Ar), 7.08–7.16 (m, 1H, Ar), 7.29–7.39 (m, 
2H, Ar), 7.66 (d, 2H, J = 8.0 Hz, Ar), 7.80 (d, 2H, J = 8.5 Hz, Ar), 8.04 (broad s, 1H, 
NH); 
13
C NMR (CDCl3): δ 27.8 ((CH3)3), 43.2 (CH2), 83.0 (C(CH3)3), 120.0, 121.2, 
123.9, 127.8, 128.1, 128.8, 138.3, 140.2 (Ar), 149.8 ((CH3)3COCO), 151.9 (CN), 165.3 
(PhNHCOPh). 
 
Hydrochloride salt of 4-(2-imidazolidinylimino)benzanilide (22b). Following 
method B, 158 mg (94%) of the pure hydrochloride salt of 22b were obtained as a 
white solid; mp decomposes over 270 °C; MS (ESI
+
) m/z 281.1369 [M+H]
+
; 
1
H NMR 
(D2O): δ 3.71 (s, 4H, CH2), 7.22–7.32 (m, 3H, Ar), 7.41–7.52 (m, 4H, Ar), 7.74–7.83 
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(m, 2H, Ar); 
13
C NMR (D2O): δ 42.1 (CH2), 121.7, 121.8, 125.3, 128.6, 128.7, 130.7, 
136.3, 138.4 (Ar), 157.0 (CN), 167.3 (CO); Anal. (C16H17ClN4O
.
1.0H2O) C, H, N.  
 
4’-[2,3-di(tert-butoxycarbonyl)guanidino]benzanilide (23d). Method A with 896 
mg (3.3 mmol) of HgCl2, 637 mg (3.0 mmol) of 4'-aminobenzanilide, 830 mg (3.0 
mmol) of N,N’-di(tert-butoxycarbonyl)thiourea and 1.3 mL (9.3 mmol) of Et3N in 
CH2Cl2:DMF (5:1) (6 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and 
22 h more at room temperature. The reaction was worked up and purified by silica gel 
column chromatography, eluting with hexane:EtOAc (3:1) to yield 850 mg (62%) of 
23d as a white solid.  
Method C: 0.28 mL (2.0 mmol) of Et3N and 0.23 mL (2.0 mmol) of benzoyl chloride 
were added under an inert atmosphere and at 0 °C over a solution of 701 mg (2.0 mmol) 
of 4-[2,3-di(tert-butoxycarbonyl)guanidino]aniline 8 in dry CH2Cl2 (10 mL). The 
reaction mixture was allowed to reach room temperature and stirred for 16 h. Then, 20 
more mL of CH2Cl2 were added and the organic phase was washed with water (2 × 15 
mL) and dried over anhydrous Na2SO4. The solvent was removed in vacuo and the 
residue obtained was purified by silica gel column chromatography, eluting with 
hexane:EtOAc (3:1) to yield 820 mg (90%) of 23d as a white solid;  mp > 300 °C; MS 
(ESI
+
) m/z 477.2126 [M+Na]
+
; IR (nujol) ν 3379, 3261, 3170 (NH), 1718, 1645, 1627, 
1575 (CO, CN) cm
-1
; 
1
H NMR (CDCl3): δ 1.36 (s, 9H, (CH3)3), 1.57 (s, 9H, (CH3)3), 
7.25 (d, 2H, J = 9.0 Hz, Ar), 7.38–7.52 (m, 3H, Ar), 7.56 (d, 2H, J = 8.5 Hz, Ar), 7.81 
(d, 2H, J = 7.0 Hz, Ar), 8.74 (broad s, 1H, PhNHCOPh), 10.03 (broad s, 1H, NHGu), 
11.50 (broad s, 1H, NHGu); 
13
C NMR (CDCl3): δ 27.9, 28.0 ((CH3)3), 79.7, 83.7 
(C(CH3)3), 120.7, 124.5, 127.1, 128.2, 131.6, 131.2, 135.5, 136.5 (Ar), 153.0, 154.8 
((CH3)3COCO), 163.1 (CN), 166.0 (PhNHCOPh). 
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4’-[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]benzanilide (23e). Method 
A with 896 mg (3.3 mmol) of HgCl2, 637 mg (3.0 mmol) of 4'-aminobenzanilide 23, 
907 mg (3.0 mmol) of N,N’-di(tert-butoxycarbonyl)imidazolidine-2-thione and 1.3 mL 
(9.3 mmol) of Et3N in CH2Cl2:DMF (5:1) (6 mL) at 0 °C. The resulting mixture was 
stirred at 0 °C for 1 h and 25 h more at room temperature. The reaction was worked up 
and purified by neutral alumina column flash chromatography, eluting with 
hexane:EtOAc (3:7). The residue obtained after the column was recrystallised from 
EtOAc to yield 697 mg (48%) of 23e as a white solid; mp 115–117 °C; IR (nujol) ν 
3309 (NH), 1752, 1718, 1696 (CO, CN) cm
-1
; 
1
H NMR (DMSO–d6): δ 1.30 (s, 18H, 
(CH3)3), 3.77 (s, 4H, CH2), 6.85 (d, 2H, J = 8.5 Hz, Ar), 7.49–7.62 (m, 3H, Ar), 7.67 (d, 
2H, J = 8.0 Hz, Ar), 7.98 (d, 2H, J = 7.0 Hz, Ar), 10.14 (broad s, 1H, NH); 
13
C NMR 
(DMSO–d6): δ 28.8 ((CH3)3), 44.2 (CH2), 82.7 (C(CH3)3), 122.0, 122.1, 128.9, 129.6, 
132.6, 134.9, 136.4, 140.3 (Ar), 145.8 ((CH3)3COCO), 151.0 (CN), 166.3 
(PhNHCOPh). 
 
Hydrochloride salt of 4’-(2-imidazolidinylimino)benzanilide (23b). Following 
method B, 157 mg (96%) of the pure hydrochloride salt of 23b were obtained as a 
white solid; mp decomposes over 180 °C; MS (ESI+) m/z 281.1369 [M+H]
+
; 
1
H NMR 
(D2O): δ 3.70 (s, 4H, CH2), 7.23 (d, 2H, J = 8.6 Hz, Ar), 7.48–7.58 (m, 4H, Ar), 7.60–
7.65 (m, 1H, Ar), 7.80 (d, 2H, J = 7.0 Hz, Ar); 
13
C NMR (D2O): δ 42.1 (CH2), 122.8, 
124.2, 126.9, 128.3, 131.5, 132.0, 133.0, 135.4 (Ar), 158.0 (CN), 168.9 (CO); Anal. 
(C16H17ClN4O
.
0.5H2O) C, H, N.  
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4-[2,3-di(tert-butoxycarbonyl)guanidino]acetophenone (30d). Method A, with 896 
mg (3.3 mmol) of HgCl2, 406 mg (3.0 mmol) of 4-aminoacetophenone 30, 830 mg (3.0 
mmol) of N,N’-di(tert-butoxycarbonyl)thiourea and 1.3 mL (9.3 mmol) of Et3N in DMF 
(5 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and 41 h more at room 
temperature. The reaction was worked up and purified by silica gel column 
chromatography, eluting with hexane:EtOAc (3:1) to yield 943 mg (83%) of 30d as a 
white solid; mp = decomposes over 176 °C; IR (nujol) ν 3278, 3146 (NH), 1718, 1686, 
1637, 1598 (CO, CN) cm
-1
; 
1
H NMR (CDCl3): δ 1.51 (s, 9H, (CH3)3), 1.53 (s, 9H, 
(CH3)3), 2.55 (s, 3H, CH3), 7.74 (d, 2H, J = 8.5 Hz, Ar), 7.92 (d, 2H, J = 8.0 Hz, Ar), 
10.56 (broad s, 1H, NH), 11.61 (broad s, 1H, NH); 
13
C NMR (CDCl3): δ 26.3 (CH3), 
27.9, 28.0 ((CH3)3), 79.9, 84.0 (C(CH3)3), 121.0, 129.3, 132.9, 141.2 (Ar), 153.1 
((CH3)3COCO), 163.1 (CN), 196.8 (CH3CO). 
 
4-[1,3-di(tert-butoxycarbonyl)-2-imidazolidinylimino]acetophenone (30e). 
Method A, with 896 mg (3.3 mmol) of HgCl2, 406 mg (3.0 mmol) of 4-
aminoacetophenone 30, 907 mg (3.0 mmol) of N,N’-di(tert-
butoxycarbonyl)imidazolidine-2-thione and 1.3 mL (9.3 mmol) of Et3N in DMF (5 mL) 
at 0 °C. The resulting mixture was stirred at 0 °C for 1 h and 25 h more at room 
temperature. The reaction was worked up and purified by neutral alumina column flash 
chromatography, eluting with hexane:EtOAc (3:2). The residue obtained after the 
column was precipitated with Et2O and washed with cold hexane to yield 613 mg (50%) 
of 30e as a white solid; mp 113–115 °C; IR (nujol) ν 1744, 1705, 1670 (CO, CN) cm-1; 
1
H NMR (CDCl3): δ 1.31 (s, 18H, (CH3)3), 2.53 (s, 3H, CH3), 3.84 (s, 4H, CH2), 6.99 
(d, 2H, J = 8.0 Hz, Ar), 7.85 (d, 2H, J = 8.0 Hz, Ar); 
13
C NMR (CDCl3): δ 26.3 
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(CH3), 27.8 ((CH3)3), 43.2 (CH2), 83.0 (C(CH3)3), 121.0, 129.4, 131.2, 140.2 (Ar), 
149.8 ((CH3)3COCO), 153.3 (CN), 197.1 (CH3CO). 
 
DNA binding assays. Thermal melting experiments were conducted with a Varian 
Cary 300 Bio spectrophotometer equipped with a 6x6 multicell temperature-controlled 
block. Temperature was monitored with a thermistor inserted into a 1-mL quartz curvet 
containing the same volume of water as in the sample cells. Absorbance changes at 260 
nm were monitored from a range of 20 ºC to 95 ºC with a heating / cooling rate of 0.5 
ºC/min and a data collection rate of two points per ºC. The poly(dA)•poly(dT) DNA 
polymer was purchased from Amersham Pharmacia Biotech Inc, NJ, USA (extinction 
coefficient ε260 = 6000 cm
-1
M
-1
 base). A quartz cell with a 1-cm path length was filled 
with a 1-mL solution of DNA polymer or DNA–compound complex. The DNA 
polymer (40 µM base) and the compound solution (12 µM) were prepared in a low salt 
buffer (0.01 M [2-(N-morpholino)ethanesulfonic acid], 0.001 M disodium EDTA, 
adjusted to pH 6.25) so that a compound to DNA base ratio of 0.3 was obtained. This 
effectively saturates all minor groove binding sites for these compounds. The thermal 
melting temperatures of the duplex or duplex–compound complex obtained from the 
first derivative of the melting curves are reported.  
 
Ferriprotoporphyrin IX biomineralisation inhibition test (FBIT). The FBIT was 
performed according to Deharo et al..
16
 In a 96-well plate were incubated at 37 °C for 
18–24 h a mixture containing: 50 µL of 0.5 mg/mL of haemin chloride (Sigma H 5533) 
freshly dissolved in DMSO, 100 µL of 0.5 M sodium acetate buffer (pH 4.4) and 50 µL 
of different concentrations of drug solution or 50 µL of solvent (for control). The plate 
was centrifuged at 1600 × g for 5 min and the supernatant was discarded. The remaining 
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pellet was resuspended with 200 µL of DMSO to eliminate unreacted haemin. Then, the 
plate was centrifuged once again and the supernatant similarly discarded. The 
precipitate (β-haematin), was dissolved in 150 µL of  0.1 N NaOH and the absorbance 
was read at 405 nm with an ELISA reader (ELX 800 Biotech Instruments). The 
percentage of inhibition of ferriprotoporphyrin IX biomineralisation was calculated with 
the following equation: 
Inhibition (%) = 100 × [(Abs. control − Abs. drug)/ Abs. control] 
IC50 values were determined using the TENDANCE function of Excel program. 
 
In Vitro Activity against T. brucei rhodesiense STIB900.  This trypanosoma strain 
was isolated in 1982 from a human patient in Tanzania. Minimum Essential Medium 
(50 µl) supplemented with 25 mM HEPES, 1g/L additional glucose, 1% MEM non-
essential amino acids (100x), 0.2 mM 2-mercaptoethanol, 2mM Na-pyruvate, 0.1mM 
hypoxanthine and 15% heat inactivated horse serum was added to each well of a 96-
well microtiter plate. 3-fold serial drug dilutions were prepared in duplicate in the 
columns covering a range from 90 µg/mL to 0.123 µg/mL. Then 104 bloodstream forms 
of T. b. rhodesiense STIB 900 in 50 µL was added to each well and the plate incubated 
at 37 °C under a 5% CO2 atmosphere for 72 h. 10 µL of resazurin solution (12.5 mg 
resazurin dissolved in 100 mL distilled water) were then added to each well and 
incubation continued for a further 2–4 hours. Then the plates were read with a 
Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an emission wave 
length of 588 nm. Data were analyzed using the microplate reader software Softmax Pro 
(Molecular Devices Cooperation, Sunnyvale, CA, USA). 
In Vitro Activity against P. falciparum K1. In vitro activity against erythrocytic 
stages of P. falciparum was determined using a 
3
H-hypoxanthine incorporation assay, 
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using the chloroquine and pyrimethamine resistant K1 strain and the standard drug 
chloroquine (Sigma C6628). Compounds were dissolved in DMSO at 10 mg/mL and 
added to parasite cultures incubated in RPMI 1640 medium without hypoxanthine, 
supplemented with HEPES (5.94 g/L), NaHCO3 (2.1 g/L), neomycin (100 U/mL), 
Albumax (5 g/L) and washed human red cells A
+
 at 2.5% haematocrit (0.3% 
parasitaemia). Serial doubling dilutions of each drug were prepared in 96-well 
microtiter plates and incubated in a humidified atmosphere at 37 °C; 4% CO2, 3% O2, 
93% N2. After 48 h 50 µL of 
3
H-hypoxanthine (= 0.5 µCi) was added to each well of the 
plate. The plates were incubated for a further 24 h under the same conditions. The plates 
were then harvested with a Betaplate cell harvester (Wallac, Zurich, Switzerland), and 
the red blood cells transferred onto a glass fibre filter then washed with distilled water. 
The dried filters were inserted into a plastic foil with 10 mL of scintillation fluid, and 
counted in a Betaplate liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 
values were calculated from sigmoidal inhibition curves using Microsoft Excel. 
In Vitro Cytotoxicity with L–6 cells. Assays were performed in 96-well microtiter 
plates, each well containing 100 µL of RPMI 1640 medium supplemented with 1% L-
glutamine (200 mM) and 10% fetal bovine serum, and 4 x 10
 4
 L–6 cells (rat skeletal 
myoblasts) with or without a serial drug dilution columns covering a range from 90 
µg/mL to 0.123 µg/mL. Each compound was tested in duplicate. After 72 h of 
incubation the plates were inspected under an inverted microscope to assure growth of 
the controls and sterile conditions. 10 µL of Alamar Blue (12.5 mg resazurin in 100 mL 
phosphate buffered saline) was then added to each well and the plates incubated for 
another 2 h. Then the plates were read with a Spectramax Gemini XS microplate 
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation 
wave length of 536 nm and an emission wave length of 588 nm. Data were analysed 
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using the microplate reader software Softmax Pro (Molecular Devices Cooperation, 
Sunnyvale, CA, USA). 
In Vivo Activity against T. brucei. All efficacy studies were approved by the 
institutional animal experimentation ethics committee.  Female NMRI mice weighting 
22–25 g were infected with cryopreserved stabilates of T. brucei rhodesiense STIB 900. 
Each mouse was infected intraperitoneally with 2 × 10
4
 (STIB 900) bloodstream forms. 
Groups of four mice were treated intraperitoneally with the compounds on days 3, 4, 5, 
and 6. A control group remained untreated. The parasitemia of all animals was checked 
every second day up to day 14 post-infection and two times a week thereafter until 60 
days. Death of animals was recorded to calculate the mean survival time. Surviving and 
aparasitemic mice were considered cured at 60 days and then euthanized. 
In vivo antimalarial efficacy studies. All efficacy studies were approved by the 
institutional animal experimentation ethics committee. In vivo antimalarial activity was 
assessed basically as previously described.
51
 Groups of three female NMRI mice (20–22 
g) intravenously infected with 2 x 10
7
 parasitized erythrocytes on day 0 with GFP-
transfected P. berghei strain ANKA.
52
 Compounds were formulated in 100% DMSO, 
diluted 10-fold in distilled water and administered intraperitoneally in a volume of 10 
mL kg
-1
 on four consecutive days (4, 24, 48 and 72 h post infection). Parasitemia was 
determined on day 4 post infection (24h after last treatment) by FACS analysis. Activity 
was calculated as the difference between the mean per cent parasitaemia for the control 
(n = 5 mice) and treated groups expressed as a per cent relative to the control group. 
The survival time in days was also recorded up to 30 days after infection. A compound 
was considered curative if the animal survived to day 30 after infection with no 
detectable parasites. 
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X = PhCO- (19), PhNHCONH- (20),
PhNHCSNH- (21), PhNHCO- (22),
PhCONH- (23), CH3CO- (30)
X
N
H
N
H
N
H
N
N
HN ZZ
20a, 21a: Z = nil
20b, 21b: Z = CH2CH2
TFA salt
HCl salt
b
c
19a, 22a, 23a, 30a: Z = nil
19b, 22b, 23b, 30b: Z = CH2CH2
19d, 20d, 21d, 22d, 23d, 30d: Z = nil
19e, 20e, 21e, 22e, 23e, 30e: Z = CH2CH2
X
N
H
N
HN Z
Reagents and conditions: (a) N,N' -di(ter t-butoxycarbonyl)thiourea or N,N'-di(ter t-butoxycarbonyl)imidazoline-2-thione, HgCl2, Et3N, solvent; (b)
CH2Cl2/TFA (1:1); (c) IRA400 (Cl-) Amberlyte anion exchange resin; (d) CS2, CH2Cl2, 50ºC; (e) Phenylisothiocyanate (21d) or phenylisocyanate(20d) or benzoylchloride (23d), CH2Cl2, 0ºC then rt, 18h.
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Reagents and conditions: (a) H2, Pd-C 5%, MeOH, rt; (b) HNO3, H2SO4;
(c) 1-fluoro-4-nitrobenzene, DMF, 100ºC, 72h; (d) Phenylisocyanate,
CH2Cl2, 0ºC; (e) Aniline, Et3N, TBTU, CH2Cl2; (f) TFA, CH2Cl2.
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X
NN
Fused ring system: increased activity
(Y = CH2, nil)
T .b.r . : Increased activity for X = CH2CH2, NH, NHCO
P. f . : Reduced activity for X = SO2 or NHCSNH;
Best activity for electron-rich phenyl rings
N
H
N
Imidazoline cations:
- better safety profile
- more active in vivo
N
N
R
R
Lipophilic bulky substituent
(Boc) is allowed
Y
2 cations >> 1 cation
 
 
 
Figure 3. SAR against T. b. rhodesiense and P. falciparum 
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Figure 1. Plot of log(1/IC50) vs ∆Tm showing the correlation between in vitro 
antitrypanosomal activity and Tm increase for the set of bis(2-aminoimidazoline) 
compounds: (a) Y= 0.0857x - 4.8776; R = 0.9056,  and the set of bisguanidine 
derivatives: (b) Y= 0.03767x – 3.0968; R = 0.5994.  
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Figure 2. Plot of SI vs Tm for the bis(2-aminoimidazoline) compounds showing a good 
correlation between in vitro selectivity (SI = IC50 L6–cells / IC50 T. brucei) and Tm 
increase: (■) 1b, 2b, 3b, 4b, 7b, 9b, 10b, 11b, 12b, 13b, and 14b.  
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Table 1. In vitro antitrypanosomal and antiplasmodial activity of diphenyl dicationic  
compounds (scaffold A). 
R
X
R
X 1
2
3
4
5
6
Y
R
4'R
1-12 13-14
 
 
IC50 (µM) Cpd Ra X Y  
T.b.r.
b
 P.f. 
c
 Cytotoxicity 
L6-cells 
1a Gua  - 0.022
d
 0.018 0.65 
1b Imi  - 0.069
d 
0.0088 212 
1c (EtO)2CHCH2-Gua NH - 0.228
d 
0.113 > 175 
1d (Boc)Gua  - 0.470
d 
0.077 3.7 
1e (Boc)Imi  - 0.048
d 
0.059 9.8 
2a Gua  - 0.161
d
 0.032 2.8 
2b Imi CH2 - 0.897
d 
0.0157 63.6 
2c (EtO)2CHCH2-Gua  - 0.316
d
 0.036 > 175 
3a Gua O - 0.196 0.046 1.64 
3b Imi  - 0.467 0.038 41 
4a Gua S - 0.102 0.035 2.66 
4b Imi  - 0.386 0.025 23.3 
5a Gua - 0.206
d 
0.068 2.7 
5b Imi - 2.05
d 
0.129 > 214 
5f CH2P
+
(n-pentyl)3 
 
O
 - 0.414
d
 0.053 11.8 
6a Gua - 4.3
d 
0.444 > 222 
6b Imi - 32.4
d 
5.6 > 196 
6e (Boc)Imi 
 
S
O O
 - 2.6
d
 0.055 56.4 
7a Gua - 0.187 0.096 > 235  
7b Imi NH
N
H
O
 - 0.122 0.028 104 
8a Gua N
H
N
H
S
 
- 0.538 0.607 15.5 
9a Gua - 0.036 0.055 11.5 
9b Imi NH
O
 
- 0.025 0.028 193 
10a Gua - 0.045 0.019 1.09 
10b Imi 
 
- 0.054 0.016 34.9 
11a Gua - 0.217 0.041 24 
11b Imi 
N
 - 0.038 0.011 132 
12a Gua - 0.270
d 
0.0152 46.4 
12b Imi 
N N
 - 0.118
d 
0.0123 104 
13a 4,4’-Gua nil CH2 0.024
e
 0.0023
e
 4.7
e 
13b 4,4’-Imi nil CH2 0.0049 0.0115 83.4 
14a 5,4’-Gua CH2 CH2 0.050 0.0088 0.73 
14b 5,4’-Imi CH2 CH2 0.060 0.0186 37.2 
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a
 Gua =
NH
NH2
HN
, Imi =
N
NH
NH , (Boc)Gua =
NH
H
NN
tBuO2C
CO2tBu
,  
(Boc)Imi = 
N
N
N CO2
tBu
tBuO2C
; 
b
 T. brucei rhodesiense STIB900 strain. Control: 
melarsoprol, IC50 = 5.5 nM; 
c
 P. falciparum K1 strain. Control: chloroquine, IC50 = 
0.278 µM. d Data previously reported in ref. 8 and included here for comparison 
purposes; 
e
 Data taken from ref. 13. 
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Table 2. In vitro antitrypanosomal and antiplasmodial activity of diphenyl 
monocationic compounds (scaffold B). 
 
X
R  
 
IC50 (µM) Cpd Ra X 
T.b.r.
b
 
 
P.f. 
c
 Cytotoxicity 
L6-cells 
15a Gua NH 4.8 1.6 49.5 
15b Imi NH 1.2 0.549 90.7 
16a Gua CH2 15.9 3.8 43.9 
16b Imi CH2 4.9 1.7 73.0 
17a Gua O 18.8 7.9 59.9 
17b Imi O 5.0 5.7 166.7 
18b Imi S 1.9 1.2 28.5 
19a Gua CO 14.4 > 18 118.1 
19b Imi CO 9.4 5.2 225.8 
20a Gua NH-CO-NH 32.9 4.1 > 234 
20b Imi NH-CO-NH 45.4 3.4 > 219 
21a Gua NH-CS-NH 1.3 8.7 > 225 
21b Imi NH-CS-NH 2.6 3.1 91.1 
22a Gua NH-CO 87.4 13.3 > 309 
22b Imi NH-CO 42.9 > 15 > 284 
23a Gua CO-NH 121.7 10.4 > 309 
23b Imi CO-NH 94.7 > 15 > 284 
a 
Gua =
NH
NH2
HN
, Imi =
N
NH
NH ; 
b
 T. brucei rhodesiense STIB900 strain. Control: 
melarsoprol, IC50 = 5.5 nM; 
c
 P. falciparum K1 strain. Control: chloroquine, IC50 = 
0.278 µM. 
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Table 3. In vitro antitrypanosomal and antiplasmodial activity of phenyl monocationic 
compounds (scaffold C). 
X
RY  
 
X Y IC50 (µM) Cpd Ra 
  T.b.r.
b
 
 
P.f. 
c
 Cytotoxicity 
L6-cells 
24a Gua NH2 H 311.2 > 26 131.8 
25b Imi NH2 H nd 15.0 > 423 
25a Gua (CH3)2NH H 20.1 > 19 > 358 
25b Imi (CH3)2NH H 46.6 > 18 > 324 
26a Gua Et2NH H 2.4 5.7 78.1 
26b Imi Et2NH H 40.1 15.0 > 444 
27a
d 
Gua CH3 H 163.7 > 27 > 484 
27b Imi CH3 H 262.4 > 23 > 425 
28a Gua Et H 45.7 9.0 309.6 
29a Gua CH3S H 5.9 1.3 239.7 
29b Imi CH3S H 7.3 1.7 173.9 
30a
d 
Gua CH3CO H 155.4 > 23 > 421 
30b Imi CH3CO H 54.6 5.7 > 375 
31a Gua 4-piperidin-1-yl H 48.6 7.9 231.8 
31b Imi 4-piperidin-1-yl H 50.4 12.0 > 283 
32a Gua Fused cyclopentane  0.99 0.95 73.7 
32b Imi Fused cyclopentane 9.2 5.3 > 378 
33a Gua Fused 1,4-dioxane 149.8 9.0 > 391 
33b Imi Fused 1,4-dioxane 68.4 > 19 > 351 
34a
d 
Gua Fused 1,3-dioxolane 146.0 > 23 > 417 
34b Imi Fused 1,3-dioxolane 93.5 > 20 > 372 
35a
d 
Gua CH3O CH3O 237.0 14.8 > 388 
35b Imi CH3O CH3O 84.2 14.8 > 349 
36a Gua CH3 CH3 39.9 12.2 189.8 
36b Imi CH3 CH3 49.8 17.1 > 398 
37b Imi H H 181.8 > 25 > 455 
a
 Gua =
NH
NH2
HN
, Imi =
N
NH
NH ; 
b
 T. brucei rhodesiense STIB900 strain. Control: 
melarsoprol, IC50 = 5.5 nM; 
c
 P. falciparum K1 strain. Control: chloroquine, IC50 = 
0.278 µM; d the antiplasmodial action against P. gallinaceum in chicks had been studied 
before by King, H. and Tonkin, I. M. J. Chem. Soc. 1946, 1063-1069. 
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Table 4. In Vivo Antitrypanosomal Activity in the T. b. rhodesiense (STIB900) mouse 
model. 
 
 
 
 
 
 
 
 
a
 See experimental section for details of STIB 900 (T. b. rhodesiense) model. 
b
 ip = 
intraperitoneal. 
c
 Number of mice that survive and are parasite free for 60 days. 
d
 
Average days of survival.  
 
Compound Dosage 
route
b
 
Dosage 
(mg/kg) 
Cured
c
/Infected Survival  
(days)
d
 
Control - - 0/4 7.5 
7b ip 4 × 20  4/4 > 60 
9a ip 4 × 20 4/4 > 60 
9b ip 4 × 20 4/4 > 60 
10b ip 4 × 20 4/4 > 60 
11b ip 4 × 20 2/4 > 47.25 
14b ip 4 × 20 4/4 > 60 
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Table 5. In Vivo Antiplasmodial Activity in the P. Berghei (ANKA GFP) mouse 
model. 
Compound Dosage 
route
b
 
Dosage 
(mg/kg) 
Cured
c
/Infected % of 
activity
d
 
Survival  
(days)
e
 
Control - - 0/4 - 6.2 
 
Chloroquine ip 4 × 5 0/4 99.6 9 
 ip 4 × 10 0/4 99.6 20 
1b ip 4 × 20  0/4 65.51 7
 
2b ip 4 × 20 0/4 8.9 6.7
 
3b ip 4 × 30 0/4 44.1 7
 
4b ip 4 × 50 0/4 97.5 11.3
 
7a ip 4 × 50 T
f 
T - 
10a ip 4 × 50 T T - 
11a ip 4 × 50 T T - 
12a ip 4 × 20 0/4 42.48 7
 
12b ip 4 × 20 0/4 0 7
 
14a ip 4 × 50 T T - 
a
 See experimental section for details of ANKA GFP (P. berghei) models. 
b
 ip = 
intraperitoneal. 
c
 Number of mice that survive and are parasite free for 60 days. 
d
 % of 
reduction of parasitaemia. 
e
 Average days of survival. 
f 
Toxic at the dose tested. 
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Table 6. DNA binding affinity and selectivity index of the diphenyl dicationic 
compounds. 
R
X
R
X 1
2
3
4
5
6
Y
R
4'R
1-12 13-14
 
 
∆Tm (ºC)a Selectivity 
index
c
 
Cpd R X Y  
poly(dA•dT)2 (SI) 
1a Gua  - 29.6
b
 30 
1b Imi NH - 38.5
 b
 3072 
1c (EtO)2CHCH2-Gua  - 13.6
 b
 > 767 
2a Gua  - 15.0
 b
 17 
2b Imi CH2 - 18.8
 b
 71 
2c (EtO)2CHCH2-Gua  - 5.3
 b
 > 553 
3a Gua O - 22.1 8 
3b Imi  - 27.1 88 
4a Gua S - 20.1 26 
4b Imi  - 24.1 60 
5a Gua - 27.6 
b
 13 
5f (n-pentyl)3P
+
 
O
 - 1.2
 b
 29 
6a Gua - 12.8
 b
 > 51 
6b Imi 
S
O O
 - 12.1
 b
 > 6 
7a Gua - 24.1 > 1256 
7b Imi NH
N
H
O
 - 31.0 852 
8a Gua N
H
N
H
S
 
- 23.0 29 
9a Gua - 40.1 319 
9b Imi NH
O
 
- 47.1 7720 
10a Gua - 26.1 24 
10b Imi 
 
- 31.2 646 
11a Gua - 30.0 111 
11b Imi 
N
 - 35.0 3474 
12a Gua - 27.8 
b 172 
12b Imi 
N N
 - 38.8 
b 881 
13b 4,4’-Imi nil CH2 44.1 17020 
14a 5,4’-Gua CH2 CH2 31.1 15 
14b 5,4’-Imi CH2 CH2 33.2 620 
a 
Pentamidine: ∆Tm = 32.3 ºC (see ref. 7). b Data taken from ref. 7. c Selectivity index = 
IC50 (L6-cells) / IC50 (T. b. rhodesiense). 
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